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Abstract
Sibomana Isaie, Ph.D., Biomedical Sciences Ph.D. Program, Wright State University,
2016. Evidence that myo-inositol plus ethanolamine elevates plasmalogen levels and
lends protection against oxidative stress in Neuro-2A cells

Plasmalogens are glycerophospholipids abundant in brain and heart tissues.
Evidence suggests that they have antioxidant properties. Studies from our laboratory
showed that rats treated with myo-inositol plus ethanolamine (ME) have elevated
ethanolamine plasmalogens (PE-Pls) in brain and are protected against phosphineinduced oxidative stress. We hypothesized that ME elevates PE-Pls levels and protects
against oxidative stress through oxidation of its vinyl ether bond. We tested this
hypothesis in Neuro-2A cell culture and assessed the effects of treatments with myoinositol (M), ethanolamine (Etn), or a combination (ME) on the: (1) effects on
phospholipid (PL) classes, especially Etn PLs; (2) effects on cell viability in response to
H2O2-induced oxidative stress; and (3) molecular species of Etn PLs preferentially
affected by ME and H2O2 treatments, especially PE-Pls and their degradation byproducts
– lyso-phosphatidylethanolamines (LPE). 31P NMR data show that treating the cells with
equimolar amounts (500 M) of M or Etn for 24 h did not influence PL levels, but ME
yielded a 3-fold increase in both PE-Pls and PE (p<0.001). Cells exposed to 650 M
H2O2 for 24 h decreased cell viability to 53% ± 1.7. While pretreatment with M or ME
significantly increased cell survival to 62% ± 1.2 or 80% ± 0.6, respectively (p<0.05),
Etn alone had no effect. Mass spectrometry showed that ME preferentially elevated the
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levels of PE-Pls species containing saturated fatty acids (SFA) and monounsaturated fatty
acids (MUFA) by 60%, while PE-Pls containing polyunsaturated fatty acids (PUFA)
increased by only 10%. H2O2 caused a significant decrease in PE-Pls (27%), producing a
39% increase in LPE and a 4-fold increase in glycerophosphoethanolamine (GPE), but
had no impact on PE levels, suggesting that LPE and GPE were primarily byproducts of
PE-Pls degradation. Surprisingly, all these effects were blocked by pre-treating cells with
ME prior to H2O2 exposure. Taken together, these data suggest that a preferential increase
in PE-Pls species containing SFA+MUFA in response to ME may protect cells from
H2O2-induced oxidative stress. The mechanism for this effect is unclear, but further
investigations to understand these processes may help to develop neuroprotective
approaches to alleviate the progression of neurodegenerative diseases/disorders.
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CHAPTER 1: INTRODUCTION AND SPECIFIC AIMS
1.1 Plasmalogens: Structure and Cellular Role
Plasmalogens belong to the glycerophospholipid group. They possess a vinyl
ether bond at the sn-1 position of
O

CH
O

H C

O

C R2
O

H2C

O

P

their glycerol backbone (Fig. 1).
This bond is a unique physical and
chemical characteristic feature that
distinguishes

them

from

other

phospholipids. The bond links the

CH R1

H2C

O

CH2

CH2

NH2

OFigure 1. Chemical structure of ethanolamine
plasmalogens.

fatty acyl chain at this position to the glycerol backbone. The sn-1 position of
plasmalogens usually contains a fatty acid chain of C16 or C18 length and the vinyl ether
double bond represents always the cis-isomer (1). The sn-2 position of plasmalogens
generally contains docosahexanoic acid (DHA) or arachidonic acid (ARA), which are the
reservoirs for the second messengers (docosanoid and eicosanoid molecules) (2, 3).
Plasmalogens are found in mammalian tissues and are highly abundant in heart
and brain (3). The predominant types of plasmalogens are choline plasmalogens (PC-Pls)
and ethanolamine plasmalogens (PE-Pls), which contain choline or ethanolamine as the
polar phospho-base headgroup at the sn-3 glycerol position. PE-Pls constitutes nearly 90
mol% of ethanolamine glycerophospholipid pool (4) and 22% of the phospholipids in
human brain (5). Plasmalogens are not only the reservoirs for second messengers and
structural components of the cell membrane (6), they are also involved many cellular
processes such as in ion transport (3), cholesterol efflux (7, 8), membrane fusion (9), as
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well as suppressing neuro-inflammation (10-12) and starvation-induced cell apoptosis
(13, 14). Experimental evidences suggest that they have antioxidant properties (15-20).
Studies have shown that oxidative stress plays a significant role in the pathogenesis of
neurodegenerative diseases/disorders (21, 22). An association between a decrease in PEPls and the severity of these diseases/disorders has also been documented (23, 24). A
systemic

administration

of

PE-Pls

can

abolish

lipopolysaccharide-induced

neuroinflamation and -amyloid protein accumulation in the mouse brain (10, 11).
Additionally, rats treated with myo-inositol plus ethanolamine (ME) yield an increase in
PE-Pls levels in brain and these rats are protected against phosphine-induced oxidative
stress (25, 26). However, how ME and oxidative stress-inducing agents affect the
molecular species of ethanolamine phospholipids, especially PE-Pls in neural cells
remains unknown. This information can lead to a neuroprotective approach to a wide
spectrum of stressors on brain and cognitive function, enhancing brain resiliency. The
present study was designed to address this question using a neuronal cell (Neuro-2A cell
line) culture system.
1.1 SPECIFIC AIMS
Aim 1. Measure the phospholipid contents of Neuro-2A cells, with specific
interest in PE-Pls. This aim is designed to assess if neuro-2A cells synthesize PE-Pls.
Aim 2. Examine the effects of myo-inositol alone, ethanolamine alone and myoinositol plus ethanolamine treatments on the level of myo-inositol, phosphoethanolamine
and different phospholipid classes with special interest in PE-Pls in Neuro-2A cells. The
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purpose of this aim is to assess if these treatments induce an increase in myo-inositol,
phosphoethanolamine and phospholipids with a special interest in PE-Pls in the cells.
Aim 3. Examine the effects of myo-inositol alone, ethanolamine alone and myoinositol plus ethanolamine treatments on Neuro-2A cell protection against hydrogen
peroxide-induced oxidative stress. This aim is intended to assess if cells that contain
elevated levels of PE-Pls also show protection against oxidative stress as it has been
reported in a rat model in vivo (26).
Aim 4. Examine the molecular species of ethanolamine phospholipids that are
preferentially affected by myo-inositol plus ethanolamine and H2O2 treatments, with a
special

interest

in

PE-Pls

species

and

their

degradation

by-products

(lysoglycerophosphoethanolamines and glycerophosphoethanolamines). This aim is
designed to determine the molecular species of ethanolamine phospholipids that are
preferentially affected by ME treatment and H2O2-induced oxidative stress.
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CHAPTER 2: BACKGROUND
2.1 Phospholipids in Mammalian Cells
The improvement of the analytical tools used for structural characterization of
lipids

and

their

biosynthetic enzymes
in the cells has greatly
advanced

our

understanding on the
diversity

of

the

Figure 2. General structure of phospholipids [38]

cellular membrane lipids (27, 28). The membranes of mammalian cells are complex and
highly structured. They consist of hundreds of different phospholipid species, many
different proteins,

a variety of glycolipid molecules and cholesterol (29). The most

abundant lipids in the membranes belong to the phospholipid group (30). Phospholipids
play a crucial role in membrane functions. These include giving the membrane unique
characteristics for proper function such as membrane fluidity, permeability, local
curvature, molecular packing or hydration, charge, and ability to regulate the activities of
various membrane-bound enzymes and ion-channels (31, 32). Although all membranes
do not contain the same amount of each phospholipid class, the ratios between
phospholipid classes and their molecular species can serves as a signature for various
organelles (33, 34).
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The chemical structure of glycerophospholipids consists of the glycerol backbone,
which contains fatty-acyl chains esterified at sn-1 and sn-2 positions and a phosphate
ester group at the sn-3 position attached to one of a variety of head groups (Fig. 2). A
variety of chemical moieties can serve as head groups, thus leading to a number of
different phospholipid classes
(phosphatidyl lipids) such as
phosphatidylcholines

(PC),

phosphatidylethanolamines
(PE),

phosphatidylserines

(PS),

phosphatidylinositols

(PI), and cardiolipins (CL)
(29,

30,

35,

phospholipids

36).
are

Brain
highly

PE

AAPE

PE-Pls

Figure 3. The three subclasses of ethanolamine
phospholipids [6]. See abbreviations on pages Xiii –
Xvi.

heterogeneous with a wide range of molecular species that result from the combination of
various fatty acyl chains at the sn-1 and sn-2 positions of their glycerol backbone (37).
For instance, subclasses for ethanolamine phospholipid class include 1-acyl-2-acyl-snglycero-3-phosphoethanolamine (phosphatidylethanolamine; PE), 1-alkyl-2-acyl-snglycero-3-phosphoethanolamine (plasmanylethanolamine; AAPE) and 1-alkenyl-2-acylsn-glycero-3-phosphoethanolamine

(plasmenylethanolamine

or

phosphatidylethanolamine plasmalogen; PE-Pls) (Fig. 3). The only feature that
distinguishes these subclasses is the type of linkage that attaches the acyl chain to the
glycerol backbone at the sn-1 position. This linkage involves an ester, ether and a vinyl
ether bond for PE, AAPE and PE-Pls respectively (6) (Fig. 3). Any phospholipid that
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bears a vinyl ether linkage at the sn-1 position of the glycerol backbone is termed
“plasmalogen” (6, 38). In eukaryotes, the acyl chain in sn-2 position is always linked to
the glycerol moiety via an ester linkage (36, 38). Each of the PL subclasses is even
further subdivided into various molecular species based on the characteristics of the acyl
chains attached to sn-1 and sn-2 positions of their glycerol backbone (species from the
same class contain a similar head group but differs in respect to their acyl chains). In
plasmalogens, the fatty acyl chain at the sn-1 position is typically C16:0, C18:0 or C18:1,
while that in the sn-2 position is commonly polyunsaturated (PUFA) and is mostly
occupied by docosahexaenoic acid (DHA) or arachidonic acid (ARA) (3, 5, 39-41).
2.2 Plasmalogens in Neural Membranes
Plasmalogens are very unique types of phospholipids due to the vinyl ether bond
linking the fatty acyl chain to the glycerol backbone at the sn-1 position (6, 38). At this
position, they display a cis double bond on the fatty acyl chain, just adjacent to the ether
linkage (6, 38). This bond is believed to confer special physical and chemical properties
to plasmalogens, and to the cell membranes that harbor them (42). In the membrane,
plasmalogens have a tendency of packing more closely with one another, thus reducing
the membrane fluidity and passive ion permeability (43). It has also been reported that
plasmalogens possess a property of forming an inverse hexagonal phase, a property that
is important during membrane fusion processes (44).
Plasmalogens were initially discovered by Feulgen and Voit in 1924 and
described as fuchsine-sulfurous acid staining compounds derived from tissue sections
treated with acid or mercuric chloride as a part of a method routinely used to stain the
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nucleus (6). The breakdown of plasmalogens through the oxidation of their vinyl ether
linkage yielded aldehydes that reacted with fuchsine-sulfurous acid stain, giving rise to
colored compounds inside (cytoplasm) of the cells. The term “plasmal” was then use to
describe the aldehydes present in the plasma (cytoplasm) of the cells and the compounds
that gave rise to these aldehydes were termed “plasmalogens” (6).
In mammals, the abundance of plasmalogens varies depending on the type of cells
and tissues. They account for 4-32% of the total phospholipid mass (45). They are widely
distributed throughout human and animal tissues, averaging about 18% of the total
phospholipid contents in human body and 3.5% in human serum (46). They are mostly
abundant in circulating immune cells, heart, lung, brain and neural tissues (3, 45). The
main types of plasmalogens are choline plasmalogens (PC-Pls) and ethanolamine
plasmalogens (PE-Pls) (47). PE-Pls constitute nearly 90 mol percent of myelin
ethanolamine phospholipids (4) and over 50 mol percent of these phospholipids in
neurons (4). The predominant fatty acyl chains attached to sn-1 position of plasmalogens
in mouse and human brain are usually C16:0, C18:0 and C18:1, accounting for 98-99%
of the acyl chains at this position (48-50). Phospholipids are asymmetrically distributed
in neural membranes across the plane of the plasma membrane (51). Ethanolamine
phospholipids and phosphatidylserine are localized in the inner leaflet of the membrane,
whereas choline phospholipids and sphingomyelin are more concentrated in the outer
leaflet of the membrane bilayer (32, 52). This distribution appears to be stable, as it has
been shown that when ethanolamine phospholipids and phosphatidylcholine are placed in
the outer leaflet of the membrane, the neural aminophospholipid translocase (flippase) is
able to restore their normal distribution (53, 54). Phospholipid constituents of the neural
7

membranes are rich in PUFA (51, 55). The number of double bonds in the aliphatic
groups at the sn-1 and sn-2 positions of these phospholipids is a crucial factor in dictating
the phase transition temperature of membranes and their lateral diffusion velocity, thus
playing a major role in cellular processes such as endocytosis and exocytosis, bilayer
thickness, sorting of lipids and membrane fusion (51, 55).
2.3 Biosynthesis of Ethanolamine Plasmalogens in Brain
The enzymes involved in plasmalogen biosynthesis in brain tissues have not yet
been purified and characterized. This
is due to the heterogeneity and
complexity in organization of brain
tissue, low activity of these enzymes
as

well

consuming

as

tedious

assays

and

required

time
for

characterization of their activities
(55). However, it has been reported
that the pathway leading to the
biosynthesis of plasmalogens in brain
tissues is similar to that previously
described from other tissues (56).

Figure 4. Schematic representation of the pathway
for plasmalogen biosynthesis. See text for

Several literature reports describing

nomenclature.

this pathway in non-neural tissues are now available (5, 6, 39, 40, 57). All the steps
involved in plasmalogen biosynthesis are shown in Fig. 4 and the topology of the
enzymes that carries out each step is shown in Fig. 5. The first three enzymes that initiate
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this process are located in the peroxisome, whereas enzymes that complete the process
are located on the endoplasmic reticulum (ER) (Fig. 5) (5, 40, 55). The first step is
carried out by dihydroxyacetone phosphate acyltransferase (DHAP-AT; EC 2.3.1.42;
(58)) and involves esterification of dihydroxyacetone phosphate (DHAP) at the sn-1
position with a long chain (> C10) acyl-CoA ester to form 1-acyl-DHAP (5, 6, 39, 57).
The source of DHAP in peroxisomes is unknown. However, DHAP can either be
generated inside the peroxisomes from glycerol-3-phosphate via the activity of glycerol3-phosphate dehydrogenase or transported from the cytosol (59, 60). Characterization and
activity of DHAP-AT have been reviewed (6). In the next step, Alkyl-DHAP synthase
(ADHAP-S; EC 2.5.1.26; (61, 62)) introduces an ether bond at the sn-1 position by
replacing the sn-1 fatty acid with a long chain fatty alcohol and yielding 1-alkyl-DHAP
(5, 6, 39). The source of fatty alcohol for this reaction includes dietary intake (39) and an
action of fatty acyl CoA reductase 1 and 2 (FAR 1/FAR 2) catalyzing a reduction of the
long chain acyl-CoAs (63, 64). Honsho et al. (63) have demonstrated that FAR 1 enzyme
catalyzes the rate limiting step in the biosynthesis of plasmalogens. Cheng and Russell
(64) have shown that the preferred substrates for FAR1 are saturated and unsaturated
fatty acids of 16 or 18 carbons, while FAR2 only prefers reducing the saturated fatty
acids of 16 or 18 carbons. The third step in plasmalogen biosynthesis is catalyzed by
acyl/alkyl-DHAP reductase (AADHAP-R; EC 1.1.1.101; (65, 66)) enzyme and involves a
reduction of the ketone group at the sn-2 position of 1-alkyl-DHAP to form 1-alkyl-2lyso-sn-glycero-3-phosphate (1-alkyl-sn-G3P) (5, 6, 39). DHAP-AT and ADHAP-S
enzymes are exclusively intraperoxisomal enzymes facing the peroxisomal lumen (39,
62, 67, 68), while the fatty acyl CoA reductase and AADHAP-R enzymes are bound to
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the membrane of peroxisomes on the side facing the cytosol (39) (Fig. 5). The
implication of this enzyme setting in peroxisomes is that the supply of the acyl CoA and
DHAP to DHAP-AT must either be generated inside the peroxisomes or transported from
the cytosol into peroxisomes (39). For DHAP-AT to re-use the fatty acid released by
ADHAP-S reaction, it must be re-activated to its CoA-ester form. It has been shown that
peroxisomes possess acyl CoA synthetase also known as very long-chain acyl-CoA
synthetase (VLACS), which has the ability to activate a wide range of fatty acids,
including those released by ADHAP-S (69, 70). However, it has been reported that
AADAHP-R has a dual distribution, in peroxisomes and ER (65, 71, 72). However, the
localization of AADAHP-R
seems to have less impact
on its activity since in
human and rodent cells
defective

in

assembly,

peroxisome

this

enzyme

displays a normal level of
activity (73-75).

Figure 5. Topology of the peroxisomal enzymes involved in
the biosynthesis of plasmalogens. (1) DHAP-AT; (2)

Further
plasmalogen

steps

in

biosynthesis

take place in ER. Frist, an

ADHAP-S; (3) acyl CoA reductase (long-chain alcoholforming); (4) glycerol-3-phosphate dehydrogenase; (5)
AADHAP-R; (6) peroxisomal membrane protein; (7)
VLACS [39]. See text for nomenclature and abbreviations.

acyl chain is esterified at the sn-2 position of 1-alkyl-sn-G3P by an alkyl/acyl-glycero-3phosphate acyltransferase (AAG3P-AT; EC 2.3.1.51; (76-78)), yielding 1-alkyl-2-acylsn-glycero-3-phosphate (5, 39). It has been demonstrated that this enzyme and the one
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that attaches an acyl chain at the sn-2 position of 1-acyl-glycero-3-phosphate are different
(79, 80). Substrate specificity studies carried out to assess the selectivity of AAG3P-AT
also known as alkylglycerophosphate acyltransferase (LPAAT) on different acyl-coA
species (16:0, 18:0, 18:2, 20:4, 22:4, 22:6) have shown that its specificity for acyl chains
depends on the concentration of 1-alkyl-sn-glycero-3-phosphate (its substrate) (79). This
enzyme prefers using polyunsaturated acyl-CoA over saturated species when 1-alkyl-snglycero-3-phosphate is available at low concentrations (79).

The removal of the

phosphate group is catalyzed by phosphatidic acid phosphohydrolase (PH; EC 3.1.3.4)
and

forms

1-alkyl-2-acyl-sn-glycerol

(5,

39).

Subsequently,

ethanolamine

phosphotransferase (EPT) (EC 2.7.8.1) uses cytidinediphosphate-ethanolamine (CDPethanolamine) and 1-alkyl-2-acyl-sn-glycerol as substrates in the presence of magnesium
to synthesize 1-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine (1-alkyl-acyl-GPE) (39,
81). The last step in PE-Pls synthesis involves the dehydrogenation at the C1 and C2
positon of the alkyl group in 1-alkyl-acyl-GPE and this process is catalyzed by a
cytochrome

b5-dependent

microsomal

electron

transport

system

and

a

plasmenylethanolamine desaturase (1’-desaturase; EC 1.14.99.19) enzyme (5, 6, 39).
There is no plasmenylcholine desaturase enzyme for PC-Pls synthesis (82, 83). PC-Pls is
synthesized via from PE-Pls by either a base exchange or by a removal of ethanolamine
phosphate by phospholipase C (PLC) and by choline phosphotransferase using CDPcholine (82, 84, 85).
CDP-ethanolamine is one of the substrates in the Kennedy pathway leading to the
synthesis of phosphatidylethanolamine (PE) (86, 87) (Fig. 4). Ethanolamine kinase (EK)
catalyzes the initial reaction which involves the ATP-dependent phosphorylation of
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ethanolamine to form phosphoethanolamine and ADP as products (88). The second step,
which is a rate-limiting step in this pathway requires the CTP:phosphoethanolamine
cytidylyltransferase (ECT) to combine phosphoethanolamine and CTP to form a highenergy donor CDP-ethanolamine and produces pyrophosphate as a byproduct of the
reaction.

In

the

last

step,

CDP-ethanolamine:1,2-diacylglycerol

ethanolaminephosphotransferase (EPT) combines CDP-ethanolamine with diacylglycerol
to generate PE and releases cytidinemonophosphate-ethanolamine (CMP) as a byproduct
(88). Both PE and PE-Pls species requires the availability of CDP-ethanolamine moiety
and EPT enzyme for their de novo synthesis.
2.4 Phospholipid Homeostasis in Neural Membranes
Brain tissues actively and constantly catabolize phospholipids (51). Maintaining a
phospholipid homeostasis in mammalian cells is a gigantic task because of the great
number of different molecular species of phospholipids in cell membranes and various
biological processes such as biosynthesis, degradation, remodeling and interorganelle
trafficking of these molecules (29). Establishing homeostasis requires a balance between
phospholipid catabolism, re-synthesis via re-acylation, and de novo synthesis pathways
(52). In all these processes, the brain spends about 20% of its entire ATP pool (89).
Various forms of phospholipase and lysophospholipase enzymes have been purified and
characterized from brain tissues (51, 90). These include phospholipases A1, A2, C, D and
lysophospholipase A 1 / 2 (90-99). These enzymes are grouped in two categories. Those
that hydrolyze the acyl groups (hydrolases) and those that cleave the phosphodiester bond
(phosphodiesterases). The hydrolases include phospholipase A1 (PLA1), phospholipase
A2 (PLA2), phospholipase B (PLB), and lysophospholipase A 1 / 2 (Lyso PLA 1 / 2) (99).
12

Phosphodiesterases consist of phospholipase C (PLC) and phospholipase D (PLD) (99).
PLA1 (EC 3.1.1.32) catalyzes exclusively the hydrolysis of the ester bond at the sn-1
position, thus yielding a free fatty acid and a 2-acyl lysophospholipid (51, 99). PLA2 (EC
3.1.1.4) catalyzes the hydrolysis of the acyl ester bond at the sn-2 position, thus forming a
free fatty acid and a 1-acyl lysophospholipid (51, 99), which can be re-acylated by acylCoA in the presence of acyltransferase enzyme (51). Lysophospholipids can also be
further hydrolyzed by lysophospholipases to generate free fatty acids

and

glycerophosphobases (EC 3.1.1.5) (96, 99-101). PLC (EC 3.1.4.11) catalyzes the
hydrolysis reaction of the phosphodiester bond at the sn-3 position that yields the 1,2diacylglycerol and a phosphobase, whereas PLD (EC 3.1.4.4) removes a head group from
a glycerophospholipid to form a phosphatidic acid and a free base (51, 99).
Phospholipids in neural membranes undergo a rapid de-acylation–re-acylation
process that involves activities of phospholipases and acyltransferases (51, 102, 103). The
de-acylation–re-acylation cycle continuously shuttles fatty acyl chains between molecular
species within different phospholipid subclasses, thus introducing PUFAs into these
subclasses (51). For instance, when a PLA2 hydrolyzes a phospholipid, a resulting
lysophospholipid molecule is rapidly re-acylated with a different fatty acid (51, 102,
103). In fact, this cycle is an important mechanism for neural cells to control the
saturated and PUFAs esterified to phospholipids in their membranes (104).
2.5 Role of Plasmalogens in Neurological Diseases/Disorders
In addition to being the primary constituents of cellular membranes and acting as
the binding sites for a variety of intracellular and intercellular proteins, a number of
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phospholipid molecules also serve as the precursors of the second messengers in
eukaryotic cells (105). Several investigators have reported that the sn-2 position of
plasmalogens acts as a reservoir of neuroprotective DHA (5, 39, 106) or ARA, the
storage depots for second messengers such as docosanoid and eicosanoid molecules (2,
3). Alterations in cellular levels of plasmalogens have been associated with various
pathologies such as chronic obstruction pulmonary disease (107), rhizomelic
chondrodysplasia punctate (108, 109), asthma (19), bronchopulmonary dysplasia (110),
and neurodegenerative diseases/disorders (111-118).
Since brain tissues are rich in plasmalogens, it is not surprising that a deficiency
in brain plasmalogens can be linked to various types of neurodegenerative
diseases/disorders (5). Although the physiological role of plasmalogens is not fully
understood, they are required for normal development of the central nervous system
(CNS) (51, 55). The significance of plasmalogens in neuropathologies is highlighted by
the findings that neurodegenerative disorders/diseases are associated with a decrease in
PE-Pls levels (23, 24, 119). These include cerebro-hepato-renal (Zellweger) syndrome
where a lack of peroxisomes (cellular organelles involved in plasmalogen biosynthesis)
leads to impaired cerebellar development and neuronal cell death (119, 120), impaired
neurotransmission (23), aggravation of brain injury (121), and progression of diseases
such as Alzheimer disease (111), and chronic bronchopulmonary dysplasia (110),
Parkinson’disease (112), experimental autoimmune encephalomyelitis (113), and
Niemann Pick type C disease (122). However, it is not yet known if the cellular
deficiency in plasmalogen levels is a direct cause or a downstream effect of pathology
(5). There is evidence that supports both relationships. For instance, Goodenowe and
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colleagues (111) investigated the relationship between serum PE-Pls levels, dementia
severity and pathology of Alzheimer’s disease. Their findings indicate a correlation
between PE-Pls levels and severity of Alzheimer’s disease. It has also been shown that
the affected brain regions of Alzheimer’s disease patients are deficient in PC-Pls and PEPls contents (115, 116). Moreover, there is evidence to suggest that the severity of the
disease correlates with the magnitude of the deficiency (115, 116). Cerebral
adrenoleukodystropy (cALD), the most common peroxisomal disorder that severely
affects the myelin in the CNS (114) has also been found to correlate with a decrease in
PE-Pls (123).
It is probable that a decrease in plasmalogen contents in the brain is related to
their degradation by reactive oxygen species (ROS) (5). Khan and colleagues (123)
demonstrated that reduced levels of PE-Pls lead to an accumulation of ROS in human
cALD brain tissues and a transformation of a metabolic disorder into a fatal neuroinflammatory disease. Additionally, it has been shown that oxidative stress plays a
significant role in the pathogenesis of Parkinson’s disease, a neurogenerative disorder of
the CNS (21, 22, 124). The mechanisms underlying Parkinson’s disease involve
activation of microglial cells which produce nitric oxide and superoxide during
neuroinflammatory responses (125, 126). Gaucher’s disease reflects another type of
pathological conditions characteristic of the reduction in plasmalogen levels (117, 118).
Moraitou and colleague’s study (117) demonstrated that the red blood cell membranes
from Gaucher’s disease patients exhibit significant reduction in plasmalogen contents for
both C16:0 and C18:0 fatty acyl chains at the sn-1 position. This reduction strongly
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correlates with the disease severity. All these neurogenerative diseases have in common a
reduction in cellular plasmalogen contents probably due to oxidative stress.
2.6 Antioxidant Properties of Plasmalogens
Cells generate a small amount of free radicals such as superoxide (O2.) or
hydrogen peroxide (H2O2) during their normal biological processes (57, 127-129). The
production of free radicals can be initiated extracellularly and intracellularly (57). The
presence of these free radicals in the cells together with trace amounts of transition metals
such as Fe2+ and Cu2+ can lead to production of hydroxyl radicals (HO.), a highly reactive
radical species (130, 131). A single cell can produce about 50 hydroxyl radicals every
second, thus generating 4 million of this species a day (132). Hydroxyl radicals can
attack biomolecules located in
less than a few nanometers from
their site of production (133).
Phospholipids

in

the

cell

membrane bilayer are the main
targets of these free radicals (57)
(Fig. 6). Oxidized lipids can also
exist in radical forms, thus
attacking other molecules in a

Figure 6. A hypothetical model of the membrane lipid
bilayer

showing

the

polar

head

groups

of

phospholipids The lipid bilayer acts as an initial barrier
to free radicals [57].

step known as propagation of chain reactions which can proceed through tens to
thousands of molecular intermediates (57, 129). The propagation phase is terminated by
the action of antioxidants forming non-radical products (129, 134). The impact of lipid
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oxidation on cell membranes and physiological processes of cells have been extensively
described in several reviews (135-138).
Of all brain cells, neuronal cells are particularly vulnerable to oxidative injury
because they contain high levels of PUFAs (51) and don’t possess sufficient reduced
glutathione (139). Under normal conditions, ROS are involved in maintaining cellular
“redox
homeostasis”
aimed

at

protecting cells
against
excessive
oxidative stress
(128). However,
Figure 7. Plasmalogen reaction showing antioxidant properties of PE-Pls

elevated

levels

of ROS inflict
damage

to

as proposed by Morand et al. [130]. The identity of the initiating radical
X. and that of YH were not established by these investigators. The action
of a peroxidase on the putative allylic hydroperoxide would result in the
formation of the unsaturated aldehyde and lyso-phosphatidylethanolamine

neural

that was observed.

membranes, changing not only their fluidity (140), but also decreasing activities of other
membrane actors such as membrane-bound enzymes, ion channels, and receptors (141). It
has also been reported that they are capable of inducing alteration in cell signaling (142,
143) and surface charge (51).
There is a growing support for the hypothesis that plasmalogens are natural
antioxidants that act as scavengers of free radicals in tissue and plasma (15-20). The
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protective role of PE-Pls serving as antioxidant against free ROS has been documented
(16, 144). Studies have demonstrated the sensitivity of plasmalogen’s vinyl ether bond to
a variety of oxidative agents (39, 40, 145, 146). The vinyl ether linkage is more
susceptible to oxidation than the corresponding ester bond linking the phospholipid
moieties to their glycerol backbone (3, 5, 39-41). This bond is more preferentially
affected by reactive chlorinating species as compared to the olefinic residues in sn-2
position of diacyl-phospholipids that are embedded in the hydrophobic domain of cell
membranes (19, 147, 148). This bond may be serving as a sacrificial trap for ROS that
would otherwise cause oxidative damage to membrane lipids (15, 17) (Fig. 7). Another
explanation for the susceptibility of the vinyl ether bond to oxidative attack is inherent to
its location in the cell membrane. The enol ether double bond is exposed to the
hydrophilic domain of the membrane and its sensitivity to attack by oxygen radicals is
associated with an enhanced electron density donated by oxygen to the vinyl ether bond
(148). Additionally, the hydrogen atoms attached to the carbon atom adjacent to the vinyl
ether substituent exhibit a relatively low bond dissociation energy, which makes the vinyl
ether moiety a suited target for ROS (57).
The sensitivity of a vinyl–ether bond to oxidative attack (15-20, 145, 146) has
reinforced the hypothesis that plasmalogens are natural antioxidants. It has been
suggested that plasmalogens may be acting on a wide range of free radicals such as ROS
(149) and iron-induced peroxidation (150). The peroxidized phospholipids in neural
membranes can result in a membrane-packing defect, thus, facilitating PLA2 access to the
sn-2 ester bond for hydrolysis (51). In fact, it has been shown that peroxidized
phospholipids are the better substrates for PLA2 compared to native phospholipids (151).
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This has led to a suggestion that cytosolic PLA2 (cPLA2) is involved in repairing and
restoring the physiological physicochemical state of neural membranes (51). Other
studies have demonstrated that cPLA2 preferentially hydrolyzes unoxidized over oxidized
arachidonic acid (152), suggesting that cPLA2 is not involved in cell membrane repair
function (153). Besides sacrificing their vinyl ether bonds during free radical attack, it
has also been shown that plasmalogens can block the iron-mediated peroxidation of
PUFAs (150) and copper-induced oxidation of low-density lipoproteins (144, 154).
Luoma et al. (12) have shown that plasmalogens protect internodal myelin of
mice against oxidative damage. The findings that an increase in PE-Pls level in rat brain
is protective against phosphine-induced oxidative damage (26) suggest that PE-Pls may
be a useful target in addressing health issues that are associated with plasmalogen
deficiency. Mechanisms for enhancing the baseline level of PE-Pls in the cells and
restoration to their normal level are needed.
2.7 Goal of the Present Study
The goal of this study was to (1) assess if ME treatment increases ethanolamine
plasmalogens in N2A cells and provides protection against H2O2-induced oxidative
stress, and (2) determine the molecular species of ethanolamine phospholipids (PE-Pls,
PE and LPE) that are preferentially affected by these treatments. It has been shown that
rats treated with myo-inositol plus ethanolamine yield an increase in PE-Pls level in the
brain (25, 26, 155) and these rats are protected against phosphine-induced oxidative stress
(26). However, the relationship between the level of PE-Pls and cell protection against
oxidative stress is not known. It is likely that PE-Pls exerts a control on oxidative stress
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through the oxidation of vinyl ether linkage. We used a N2A cell culture system to
investigate the impact of ME ethanolamine phospholipid species, with a special interest
in PE-Pls species and how they are affected by H2O2-induced oxidative damage. These
studies will enhance our understanding on the relationship between ethanolamine
phospholipid species, PE-Pls species in particular, and cell’s response to H2O2-induced
oxidative stress. This research may lead to a neuroprotective approach to a wide spectrum
of stressors on brain and cognitive function, enhancing brain resiliency.
2.8 Hypothesis and Strategy
It has been shown that the vinyl-ether bond of plasmalogens is highly susceptible
to oxidation and can serve as a sacrificial trap for reactive oxygen species (15-20). These
findings have led to a suggestion that plasmalogens possess antioxidant properties. The
findings reported by Kuczynski and Reo (26) raise the possibility that the vinyl-ether
linkage of PE-Pls is involved in rat brain tissue protection against phosphine-induced
oxidative damage. I, therefore, hypothesized that myo-inositol plus ethanolamine
enhances ethanolamine plasmalogen (PE-Pls) synthesis which in turn, protects the cells
against oxidative stress through oxidation of its vinyl ether bond, thus serving as a
sacrificial trap for oxidants that could otherwise damage cells.
My strategy was to test this hypothesis using a Neuro-2A cell (murine
neuroblastoma cell line) culture system. These cells have been used extensively in
screening novel compounds for neurotoxic properties and associated mechanisms (156).
They have also been used as a model system in mechanistic studies of plasmalogeninduced neuronal protection against apoptotic stimuli (13). Hossain et al. (13) have
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demonstrated that treating N2A cells with a mixture of plasmalogens (consisting of
96.5% ethanolamine plasmalogens and 2.5% choline plasmalogens) at concentrations of
5 μg/ml and 20 μg/ml abolishes serum starvation-induced cell death, enhances
phosphorylation of AKT and ERK 1/2, which are known to inhibit the cleavage of proapoptotic caspase-9 and caspase-3 (157-159) and blocks the activity of these caspases.
N2A cells were also used to study the cell viability to ascorbic acid and H2O2 (160). The
estimated LC50 for H2O2 was above 400 M (160). This cell culture system was, therefore
a suitable in vitro system to use in testing my hypothesis. I also used H2O2 to induce
oxidative stress in N2A cells. Similarly, Hardway et al. (160) and other investigators
have used H2O2 in various studies to induce oxidative stress in cells (161-164). NMR
spectroscopy and mass spectrometry analyses of cell extracts were performed to elucidate
the effects of ME and H2O2 treatments on phospholipid profiles in general and more
specifically on molecular species of PE-Pls, PE and LPE in N2A cells.
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CHAPTER 3: METHODS
3.1 Nuclear Magnetic Resonance (NMR) Analyses

3.1.1 Cell line and culture conditions

Mouse neuroblastoma derived cells (Neuro-2A) were maintained in a growth
medium consisting of Eagle’s Minimum Essential Medium (EMEM) supplemented with
10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA). They were cultured in a
humidified chamber provided with an atmosphere of 95/5% O2/CO2 at 37 °C. Cells used
in experiments were seeded in T-75 cm2 flaks (three flasks/group) at a starting density of
6

2 x10 cells per flask in a total medium volume of 15 ml. After two days, the growth
medium was discarded and cells were washed twice with 4 ml of PBS, and then supplied
with 15 ml of fresh growth medium pre-warmed to 37 oC.

3.1.2 Neuro-2A cell treatment with myo-inositol +/- ethanolamine

At 80% confluency, cells were washed twice with 4 ml of PBS and supplied with
either growth medium, medium supplemented with 500 μM myo-inositol (M), medium
supplemented with 500 μM ethanolamine (Etn), or growth medium supplemented with
500 uM myo-inositol + 500 μM ethanolamine (ME) for 24 h. Lipids were extracted from
cells as described below and an aliquot of the sample was taken for protein determination
(see below). Working stocks of Etn, M and ME were always prepared fresh using growth
medium.
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3.1.3 Neuro-2A cell treatment with hydrogen peroxide

Dose-response assays were carried out to determine a concentration that results in
approximately 50% cell death following a 24 h exposure to hydrogen peroxide (H2O2).
Cells were grown in T-75 flaks (three flasks/group) as described above. Treatment was
initiated after the cells reached 80% confluency. After washing cells twice with 4 ml of
PBS, they were then supplied with either growth medium alone (control), or medium
supplemented with various concentrations of H2O2. At 24 h, cell viability in each group
was determined using the trypan blue staining method (see details below). A
concentration that yields about 50% cell viability was chosen for subsequent H2O2
treatment experiments. A working stock solution of H2O2 was always prepared fresh
using growth medium.

3.1.4 Evaluation of cell viability

Cell viability was assessed using the trypan blue staining method. Briefly, after
discarding the growth medium, cells were washed twice with 4 ml of PBS. A volume of 2
ml of trypsin-EDTA solution was placed in each T-75 cm2 flask. The flask was subjected
to a gentle rotation to ensure that the trypsin-EDTA solution covers the monolayer of
cells. Cells were then incubated at 37o C for 3-5 minutes to allow cell detachment from
the surface of the flask. Detached cells formed a sheet and the trypsin-EDTA became
cloudy. Once about 50% of the cells had been detached and are floating in trypsin-EDTA
solution, the flask was shaken gently to release any remaining attached cells from the
flask surface. The cells were then re-suspended in 6 ml of fresh growth medium to
inactivate trypsin. Clumps or sheets of cells were disaggregated by trituration with a 10
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mL pipet. A volume of 10 μL of cells was mixed with 10 μL of 0.4% trypan blue dye
(cell/trypan blue ratio of 1:1) in a 96-well plate. Then 10 μL of this mixture was pipetted
into a counting chamber slide (Countess®; Invitrogen) to completely fill the chamber.
The slide was inserted into the automated cell counting machine (Countess®) to
determine the number of live cells and dead cells. The Countess® machine counts the
cells that are stained blue as dead cells, while those without dye are counted as live cells.
The output of Countess® includes a total cell count/ml, live cells/ml, dead cells/ml as
well as the percentage of cell viability. The number of live and dead cells in each flask
was determined by multiplying the Countess® outputs by the appropriate dilution factor
(8x). The percentage of cell viability in a treated group was calculated using the
following formula:

% of viable cells =

Number of live cells in a treated group
X 100%
Number of live cells in a control group

This method normalizes the cell viability to the control group (cells treated with growth
medium only) set at 100%. We also assume that cell density after washing with PBS is
similar in both treated and control groups if the treatment has no deleterious effects on
cell survival. Therefore, any difference in the number of live cells was presumed to be a
result of treatment effects on cell growth and/or viability.

3.1.5 Evaluation of apoptosis
Apoptosis was assessed using cell death detection ELISAPLUS, 10x kit. N2A cells
were prepared as described above in the section on “Evaluation of cell viability”. After
assessing the total number of cells and the cell viability per treatment group, 200 L of
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the re-suspended control cells were transferred into a 1.5 ml Eppendorf tube and diluted
with a fresh growth medium to obtain a concentration of 1 x 105 cells/ml (100,000
cells/ml). The dilution factor in the control group was calculated based on the number of
live cells determined by the cell viability assays. This dilution factor was used to dilute
the cells in treated groups. A volume of 200 L of treated cells were transferred into a
1.5 ml Eppendorf tube and diluted to 1 x 105 cells/ml (100,000 cells/ml using the dilution
factor calculated for the control group). The cells were centrifuged 200 x g for 10
minutes. The supernatant was carefully removed by pipetting and the pellet re-suspended
in 200 L of lysis buffer (provided in the kit) and incubated at 15 oC to 25 oC for 30
minutes. The lysate was centrifuged at 200 x g for 10 minutes. A volume of 20 L of the
lysate were carefully transferred into streptavidin-coated microplate well. Each sample
was run in triplicate. Three microplate wells served as background control (blank). Three
additional wells were also reserved for the positive control (DNA-Histone complex). A
volume of 80 L of immunoreagent solution composed of 72 L of incubation buffer, 4
L of anti-histone-biotin and 4 L of anti-DNA-peroxidase was added to each well
containing the sample, positive control and blank. The streptavidin-coated microplate was
covered with an adhesive cover foil and incubated on a microplate shaker at 300 rpm for
2 h at 25 oC. The solution was removed thoroughly by pipetting and the wells were rinsed
carefully 3x with 300 L of incubation buffer. A volume of 100 L of ABTS substrate
solution were added to each well. A volume of 5 ml of ABTS substrate solution was
prepared by dissolving 1 ABTS substrate tablet into 5 ml of substrate buffer and allowing
the solution to come to 25 oC in the dark before use. The microplate then was incubated
on a microplate shaker at 300 rpm for 10 – 20 minutes (until the color development is
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sufficient for a photometric analysis). A volume of 100 L of ABTS stop solution was
added to each well and the absorbance was measured using a microplate reader
(FlexStation® 3 reader, Molecular Devices, LLC., CA, USA) set at 405 nm for samples
and positive control and 490 nm for blank. The values from each triplicate were averaged
and the background value (blank) was subtracted from it. Apoptosis for treated groups
was calculated using the following equation:

Apoptosis =

Absorbance in treated group
Absorbance in control group

3.1.6 Lipid and aqueous phase extractions

Lipids were extracted from N2A cells grown in T-75 flasks (three flasks/group)
according to a dual phase extraction method as described by Tyagi, et al (165), but with a
slight modification to accommodate the protein assay requirements. Briefly, the cells in
each flask were washed twice with 4 ml of PBS solution at room temperature. Then 4 ml
of ice-cold methanol were added to each T-75 cm2 flask and the cells kept on ice for 5-10
min. Cells from each flask were scrapped with a rubber policeman and transferred into a
50 ml glass centrifuge tube kept on ice. The flask was rinsed with 4 ml of ice-cold
distilled-deionized water (ddH2O) and the rinse solution added to the centrifuge tube
containing the cells suspended in methanol. Since cells in each treatment group were
grown in three flasks, the vial for each group at this point contained cells suspended in 24
ml (8 ml x 3 flasks) of methanol and ddH2O. After sonicating the mixture, a 0.5 ml
aliquot was taken from the 24 ml for protein assay. Next, a volume of 11.75 ml [(24 ml –
0.5 ml) /2] of chloroform (keeping the methanol-chloroform-water ratio at 1:1:1, v/v/v)
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was added to the mixture in the 50 ml glass centrifuge tube using a glass pipette. The
sample was vigorously mixed before being transferred into a separatory funnel. The
sample was left to stand at 4oC for 17 – 24 h to allow a complete separation of lipid and
aqueous phases. The upper methanol-water phase containing the water-soluble
metabolites and the lower chloroform phase containing the lipids were carefully collected
separately. The lipid phase (chloroform phase) was collected into a dark amber vial and
the sample was evaporated to dryness by blowing a gentle stream of nitrogen gas over the
sample. This sample then was weighted to obtain the total lipid content. Dried lipid
content was re-suspended in 700 L of deuterochloroform, sealed with a black rubber
stopper (resistant to chloroform degradation), and stored at –20 oC for further processing
(see 31P NMR and UPLC-MS/MS analyses below).
The aqueous phase was placed in a lyophilizer flask and lyophilized to dryness.
The dried sample was dissolved in 2 ml of ddH2O and treated with a chelating agent
(Chelex 100; 5 g chelex/100 ml) to remove all the divalent cations that broaden the NMR
lines. The mixture was stirred for 1 h at 4 oC. The supernatant was then transferred into a
15 ml disposable centrifuge tube and centrifuged at 2000 x g (3000 rpm) for 10 minutes
at 4 oC to remove the Chelex. The supernatant was transferred back into the lyophilizer.
Fresh chelex was added to the sample and the process was repeated as described above.
After centrifugation, the supernatant was transferred into a vial of known weight and
placed in a refrigerator at 4 oC. The lyophilizer flask was rinsed three times with 2 ml of
ddH2O. Each time, the washing was transferred into the same 15 ml disposable centrifuge
tube and centrifuged at 2000 x g for 5 minutes at 4 oC. The supernatant was transferred
each time to the same vial kept in a refrigerator at 4 oC. The supernatant was then
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lyophilized to dryness. The final weight of the vial was measured to determine the mass
of the dried sample. The vial was sealed with a grey rubber stopper and stored at –20 oC
for 1H NMR analyses.

3.1.7 Protein assays

Protein concentration was determined using the bicinchoninic acid (BCA) Protein
Assay Kit (Pierce, Rockford, IL) in 96-well-plate format. Bovine serum albumin (BSA)
was used as the standard. Briefly, a 0.5 ml aliquot was taken from a mixture of scraped
cells suspended in methanol + water as described above (see lipid extraction section). To
avoid methanol interference with the protein assay, methanol was evaporated together
with water by attaching the sample-containing vial in the water bath (25 oC) and blowing
a gentle stream of nitrogen gas over the top of the vial. The sample was reconstituted
with 0.5 ml of PBS. A series of BSA concentrations was used to produce a calibration
curve. A mixture of BCA reagent and copper (II) sulfate (BSA/CuSO4 ratio of 50:1) was
added to each well containing BSA and cell samples according to BCA working
instructions. The plate was incubated at 37°C for 30 min, then the absorbance was
measured with a microplate reader (FlexStation® 3 reader, Molecular Devices, LLC.,
CA, USA) set at 562 nm. The protein concentration in the samples was calculated based
on the standard curve.
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3.1.8 Phosphorus-31 Nuclear Magnetic Resonance Spectroscopy (31P NMR) of Lipid
Extracts
Lipid extracts were removed from the -20 oC freezer and allowed to equilibrate to
room temperature. As described above (see lipid and aqueous phase extraction section),
the lipid extract for each sample was re-suspended in 700 L of CDCl3. A volume of 500
L of lipids was transferred into a 5 mm NMR tube using a glass syringe and the
remaining 200 L was saved for UPLC-MS/MS analyses. A volume of 200 L of 90 mM
Cs2EDTA-2H2O solution (dissolved in CH3OH:H2O solution; 4:1, v/v) warmed to room
temperature was added to the lipid solution in the NMR tube and mixed by inverting the
tube. An internal standard was added to this sample (10 L of 25 mM triphenylphosphate
(TPP) in CDCl3) for quantification purposes of the 31P metabolites. Proton-decoupled 31P
NMR spectra of lipid extracts were acquired in field-lock mode using a 5 mm broadband
probe operating at 242.8 MHz on a Varian Inova 600 NMR Spectrometer, using a 60o
pulse, 6982 Hz bandwidth, 1.9 s acquisition time and 4 s interpulse delay and
approximately 12 h of signal averaging (under partially saturated conditions). Spectral 31P
data were processed using exponential multiplication with 0.5 Hz line broadening and
Fourier transformation. Spectra then were baseline corrected (flattened) in MATLAB
(The Mathworks, Inc. Natick, MA; v, R2013b) using an algorithm developed in our
laboratory. The peak intensities for the metabolite signals of each spectrum then were
summed to a constant value of 1000 (sum normalization). Quantitative measures of each
phospholipid species were determined based on the known concentration of the TPP
standard. Quantification of specific metabolite resonances was accomplished using an
interactive spectral deconvolution algorithm in MATLAB as described by Anderson et al.
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(166). For quantitation purposes, the
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P signal intensities of all lipid metabolites were

corrected for T1 saturation and NOE.
3.1.9 Proton (1H) NMR of Aqueous Extracts
Dried aqueous extracts were dissolved in 700 L of known concentration of a
trimethylsilylpropanoic acid (TSP) solution in D2O. All 1H NMR spectra were acquired
on a Varian INOVA operating at 600 MHz, using a 61o pulse, 8000 Hz bandwidth, 4s
acquisition time and 6s interpulse delay with the probe temperature set to 25 oC. A total
of 1024 transients were collected per spectrum.
3.1.10 31P NMR of Aqueous Extracts
The same samples prepared for 1H NMR of aqueous extracts (see section 2.8
above) were used to acquire 31P NMR spectra using the same Varian INOVA instrument
as described above. H-1 and
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P NMR spectra were acquired in tandem experiments. P-

31 spectra were acquired using a 1H-decoupling sequence with nuclear Overhauser
enhancement (NOE) using a 60o pulse, 9708 Hz bandwidth, 1.6 s acquisition time and 3.6
s interpulse delay. The signal averaging for 31P aqueous data was approximately 12 h.

3.1.11 NMR data processing

NMR data were processed using Varian software (VNMR 6.1c) employing
exponential multiplication (producing line-broadening of 0.30 Hz and 1 Hz for 1H and 31P
spectral data respectively), Fourier transformation, and phase correction. Spectra were
then baseline corrected (flattened) in MATLAB (The Mathworks, Inc. Natick, MA; v.
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R2010b) using the Whittaker Smoother algorithm (with lambda value of 200) on selected
spectral noise regions (167, 168). Spectral regions containing resonances for water (4.70
– 5.00 ppm) were removed from 1H spectral data. The peak intensities for the metabolite
signals of each spectrum then were summed to a constant value (sum normalized).
Quantification

of

the

resonances

for

myo-inositol

(4.07

ppm;

triplet),

phosphoethanolamine (PEtn; 3.87 ppm; multiplet) and glycerophosphocholine (GPC;
3.24 ppm; singlet) was achieved using 1H spectral data. GPC (3.082 ppm, singlet) was
also quantified in
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P spectral data together with glycerophosphoethanolamine (GPE;

4.08 ppm; singlet). The quantification of all these metabolites was accomplished using an
interactive spectral deconvolution algorithm in MATLAB adapted from our previously
described methods (166). The deconvolution tool fits a defined spectral region using a
combination of tunable baseline shapes (spline, v-shaped, linear, or constant) and a
Gauss-Lorentz peak-fitting function. Integrated areas for peaks of interest then are output
to a text file. For quantitation purposes, the 1H signal intensities of myo-inositol, PEtn,
GPC and the
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P signal intensities for both GPC and GPE were corrected for T1

saturation and nuclear Overhauser enhancement (NOE). The GPC quantified using 1H
signal was used as a concentration standard for GPE.
3.2 Ultra Performance Liquid Chromatography (UPLC)-Mass Spectrometry (LCMS/MS) Analyses
3.2.1 Chemicals
Mass spectrometry grade methanol, chloroform, acetonitrile and ammonium
acetate were purchased from Sigma (St. Louis, MO). All lipid standards were purchased
from Avanti Polar Lipids, Inc. (Alabaster, AL). The internal standard 1,231

dipentadecanoyl-sn-glycero-3-phosphoethanolamine (15:0/15:0 PE; [M + H]+ = 664.0)
was used for quantification purposes of ethanolamine phospholipid molecular species.
The following compounds were used as analytical standards for the development of the
optimal eluent system, and the collision-induced dissociation (CID) energy and
fragmentation patterns of PE-Pls, PE and LPE molecular species: 1-(1Z-octadecenyl)-2docosahexaenoyl-sn-glycero-3-phosphoethanolamine (18:0p/22:6-PE plasmalogen; [M +
H]+ = 776.0); L-α-lysophosphatidylethanolamine plasmalogen (18:0p/lyso-PE; [M + H]+
= 465.6); and 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (14:0/14:0-PE, [M +
H]+ = 636.0).
3.2.2 Methods
Lipid extracts were dried by gently blowing a nitrogen gas stream over the sample
in a 25 oC water bath, weighted, and reconstituted in 700 L of CDCl3. A 500 L aliquot
of each sample was used in 31P NMR analysis and the remaining 200 L was stored for
further mass spectrometry analyses. Each sample saved for these analyses was dried by
blowing a gentle stream of nitrogen gas over the sample and re-suspended in ultrapure
methanol/chloroform solution (1:1 ratio, v/v) to a final concentration of 2.5 mg/mL. For
quantification purposes of ethanolamine phospholipid species, 30 L of each sample was
spiked with a known concentration of an internal standard (1,2-dipentadecanoyl-snglycero-3-phosphoethanolamine, 15:0/15:0 PE). Bugger (169) has reported significant
differences in ionization efficiency between phospholipid classes of ESI-MS, requiring
each phospholipid class to have its own internal standard. Some reports in the literature
have suggested the use of two or more internal standards in the analyses of each
phospholipid class since there may be a decrease in the detection efficiency as the length
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of the acyl chains increases (169-171). Deely et al. (172) have investigated this issue and
concluded that the acyl chain length has no effect on the detection efficiency. In the
current study, our focus was to identify and quantify molecular species of ethanolamine
phospholipid classes. We only used one internal standard for the quantification of the
species for all the three sub-classes of ethanolamine phospholipids (PE-Pls, PE and LPE).
Other studies have also used one internal standard to analyze each phospholipid class,
sharing a similar head group (169, 172-176). We used an internal standard that is not
naturally occurring in any significant amount in our samples, as done in other studies
(177). The diluted lipid extracts were immediately subjected to mass spectrometry
analyses. Ethanolamine phospholipids were separated from other phospholipid classes on
a Waters ACQUITY UPLC system equipped with a BEH HILIC column (Hydrophilic
interaction liquid chromatography; 1.7 m, 100 mm x 2.1mm). The temperatures were
set to 30 oC and 6 oC for column and autosampler, respectively. The mobile phase A
consisted of 50% acetonitrile

and 10 mM ammonium acetate solution pH 8.0

(acetonitrile/HPLC grade water, 50:50, v/v), while the mobile phase B contained 95%
acetonitrile and 10 mM ammonium acetate solution pH 8.0 (acetonitrile/HPLC grade
water, 95:5, v/v). Mobile phase A was prepared by adding 450 mL of water and 50 mL of
200 mM ammonium acetate solution (pH 8.0) to 500 mL of acetonitrile. Mobile phase B
was prepared by adding 50 mL of 200 mM ammonium acetate solution (pH 8.0) to 950
mL of acetonitrile. Both mobile phases A and B were degassed in an ultrasonic bath for
15 min prior to use. The injection volume was set to 5 L and the flow rate set to 0.5
mL/min. The time for UPLC ethanolamine phospholipid separations was 15 minutes per
sample using the following scheme: the initial elution was set at 100% solvent B for 0.1
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minute followed by a linear decrease to 80% during the next 10 minutes. This solvent
was then decreased to 5% during the next 1 minute (10th to 11th minute) and maintained
there for the subsequent 1 minute (11th to 12th minute). The solvent B was thereafter
increased to 100% during 1 minute (12th to 13th minute) and it was maintained there till
the end of the run (13th to 15th minute). The mass spectra were obtained by performing an
electrospray ionization tandem quadruple mass spectrometry on a Thermo TSQ Quantum
triple quadrupole LC/MS system (San Jose, CA), equipped with an electrospray ion
source and controlled by Micromass Masslynx version V4.1 software. All the samples
were run with the spray voltage and capillary temperature set to 4500 V and 200 oC,
respectively. Nitrogen was used as the drying gas at a pressure of 100 ± 20 psi. The
pressure for argon used as the collision gas was set to 1 mTorr.
All mass spectra were acquired in positive ion mode ([M + H]+). The collisioninduced dissociation (CID) energy was set to 20 eV for PE-Pls species and 16 eV for both
PE and LPE based on direct infusion data obtained for the standard compounds for each
species. Initially, the molecular species of PE-Pls, PE and LPE in the sample mixture had
to be identified to generate single reaction monitoring (SRM) transitions for each species.
The identification of the molecular species for PE-Pls was carried out by scanning for
their precursor and product ions (Table 1). When the precursor ion scan (PIS) is
performed, the product ion of choice is selected in the third quadrupole (Q3) and the
correlating precursor ion in the first quadrupole (Q1, from which the daughter ion
originates) is scanned. This PIS mode enabled an identification of all the phospholipid
parent masses for PE-Pls. Spectra for PE and LPE species were generated by scanning for
their characteristic neutral loss of their phosphoethanolamine head group (141 Da)
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(Table 2 & 3), (178). Neutral loss scans correlates the precursor ion in the first
quadrupole (Q1) and product ions in the third quadrupole (Q3) for a definite
identification of the parent mass. Except for three compounds, the 141 Da neutral loss
scanning was not used for PE-Pls analyses since it has been shown that these species
exhibit a minimal loss of 141 Da (178). As a result of this method development, single
reaction monitoring (SRM) transitions were generated for the identified molecular
species of ethanolamine phospholipids and quantitation was performed by integrating
peak intensities for each SRM transition. These experimental conditions have been
established previously (179) and used in other studies to analyze these phospholipids
(180-183). Each sample was run in triplicate. Identification of 1-lyso-2-acyl-GPE species
(lyso/16:0 and lyso/18:0) from the corresponding 1-acyl-2-lyso-GPE isomers (16:0/lyso
and 18:0/lyso) was achieved based on the elution time for these species. Okudaira et al.
(184) have reported that 1-lyso-2-acyl-GPL species elute faster than 1-acyl-2-lyso-GPL
isomers in a reverse-phase LC on CAPCELLPAK C18 ACR column. We ran our samples
on a HILIC column and expected 1-acyl-2-lyso-GPE to migrate faster than 1-lyso-2-acylGPE. Thus, the slower peaks were attributed to lyso/16:0 and lyso/18:0 species whereas
the faster peaks were assumed to be those for 16:0/lyso and 18:0/lyso. The peak area for
each molecular ethanolamine PL species and that of the internal standard were
determined using Thermo XcaliburTM software. The concentration of the molecular
species [A] (nmol/mg protein) in the sample was then calculated using the following
equation:

Concentration of [A] =

Peak area for X
X Concentration of internal standard
Peak area for internal standard
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Table 1. Experimental conditions for identification of molecular species of AAPE and
PE-Pls in N2A cells
Collision
Assignment

m/z Scan Type

Ion Mode Product

Energy (eV)

34:1-e

704.5 Neutral loss

[M + H]+ 563.5

16

36:1-e

732.4 Neutral loss

[M + H]+ 591.4

16

36:2-e

730.4 Neutral loss

[M + H]+ 589.4

16

32:0p

676.5 Precursor

[M + H]+ 364

20

32:1p

674.5 Precursor

[M + H]+ 364

20

34:1p

702.5 Precursor

[M + H]+ 339, 364, 390

20

36:1p

730.5 Precursor

[M + H]+ 339, 390, 392

20

38:1p

758.5 Precursor

[M + H]+ 392

20

34:2p

700.5 Precursor

[M + H]+ 337, 364

20

36:2p

728.5 Precursor

[M + H]+ 337, 339, 390, 392

20

36:3p

726.5 Precursor

[M + H]+ 337, 390

20

38:3p

754.5 Precursor

[M + H]+ 364, 392

20

40:3p

782.5 Precursor

[M + H]+ 392

20

36:4p

724.5 Precursor

[M + H]+ 362, 364, 369

20

38:4p

752.6 Precursor

[M + H]+ 360, 364, 390, 392

20

40:4p

780.6 Precursor

[M + H]+ 362, 390, 392

20

36:5p

722.5 Precursor

[M + H]+ 364, 367, 387

20

38:5p

750.5 Precursor

[M + H]+ 362, 364, 369, 390, 392

20

40:5p

778.5 Precursor

[M + H]+ 362, 369, 390, 392

20

38:6p

748.5 Precursor

[M + H]+ 362, 364, 367, 385, 390

20

40:6p

776.6 Precursor

[M + H]+ 362, 385, 392

20

40:7p

774.6 Precursor

[M + H]+ 362, 382, 390

20

e. ether linked (AAPE); p. plasmalogen. See abbreviations on pages Xiii - Xvi
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Table 2. Experimental conditions for identification of molecular species of PE in N2A
cells
Collision
Assignment

m/z

Scan Type

Ion Mode

Product

Energy (eV)

28:0

636

Neutral loss

[M + H]+

495.0

16

34:0

720.4 Neutral loss

[M + H]+

579.4

16

36:0

748.6 Neutral loss

[M + H]+

607.6

16

34:1

718.6 Neutral loss

[M + H]+

577.6

16

36:1

746.3 Neutral loss

[M + H]+

605.3

16

34:2

716.4 Neutral loss

[M + H]+

575.4

16

36:2

744.3 Neutral loss

[M + H]+

603.3

16

38:2

772.5 Neutral loss

[M + H]+

631.5

16

34:3

714.3 Neutral loss

[M + H]+

573.3

16

36:3

742.3 Neutral loss

[M + H]+

601.3

16

38:3

770.3 Neutral loss

[M + H]+

629.3

16

40:3

798.6 Neutral loss

[M + H]+

657.6

16

36:4

740.8 Neutral loss

[M + H]+

599.8

16

38:4

768.3 Neutral loss

[M + H]+

627.3

16

40:4

796.3 Neutral loss

[M + H]+

655.3

16

36:5

738.5 Neutral loss

[M + H]+

597.5

16

38:5

766.4 Neutral loss

[M + H]+

625.4

16

40:5

794.4 Neutral loss

[M + H]+

653.4

16

38:6

764.8 Neutral loss

[M + H]+

623.8

16

40:6

792.5 Neutral loss

[M + H]+

651.5

16

38:7

762.7 Neutral loss

[M + H]+

621.7

16

40:7

790.5 Neutral loss

[M + H]+

649.5

16

40:8

788.5 Neutral loss

[M + H]+

647.5

16

See abbreviations on pages Xiii - Xvi

37

Table 3. Experimental conditions for identification of molecular species of LPE in N2A
cells
Collision
Assignment

m/z

Scan Type

Ion Mode

Products

Energy (eV)

16:0/lyso*

454.2 Neutral loss

[M + H]+

313.2

16

18:0/lyso*

482.5 Neutral loss

[M + H]+

341.5

16

18:0p/lyso

466.1 Neutral loss

[M + H]+

325.1

16

lyso/14:0

426.5 Neutral loss

[M + H]+

285.5

16

lyso/16:0*

454.2 Neutral loss

[M + H]+

313.2

16

lyso/18:0*

482.5 Neutral loss

[M + H]+

341.5

16

lyso/20:3

504.7 Neutral loss

[M + H]+

363.7

16

lyso/20:4

502.5 Neutral loss

[M + H]+

361.5

16

lyso/22:4

530.5 Neutral loss

[M + H]+

389.5

16

lyso/20:5

500.4 Neutral loss

[M + H]+

359.4

16

lyso/22:5

528.3 Neutral loss

[M + H]+

387.3

16

lyso/22:6

526.6 Neutral loss

[M + H]+

385.6

16

* Peaks for these species were differentiated based on their elution times (see methods for
details). See abbreviations on pages Xiii - Xvi
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3.3 Statistical analyses
Levine’s and Welch’s tests were conducted to assess the equality of variances
between experimental groups for each metabolite using statistical software package
JMP® 11.0.0 (SAS Institute, Cary, NC, USA). If Levine’s test was significant (p ≤ 0.05),
then a Welch’s test was used to determine if there were significant differences in the
mean values between groups for the metabolite that was under consideration. If the
Levine’s test was not significant (NS), then the data have equal variances between groups
and Welch’s test was not applicable. Therefore, data were tested using a one-way
ANOVA (t-test). If both Levin’s and Welch’s tests were significant (p ≤ 0.05), a pairwise
Welch test was performed for all pairs of groups. All the data were considered
statistically significant at p ≤ 0.05. Data are expressed as mean ± S.E.M.
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CHAPTER 4: RESULTS AND DISCUSSION FOR NMR DATA
4.1 RESULTS
4.1.1 Phospholipid profiles in Neuro-2A cells

To determine the phospholipid profile of N2A cells, we extracted lipids from
these cells and acquired 31P NMR on the extracts (see methods for details). As shown in
Fig. 8, these cells synthesize various types of phospholipids (PL), including
phosphatidylethanolamine plasmalogens (PE-Pls) and phosphatidylcholine plasmalogens
(PC-Pls). Choline phospholipids consisting of phosphatidylcholine (PC), PC-Pls,
lysophosphatidylcholine (LPC) and 1-alkyl-2-acyl-sn-glycerophosphocholine (AAPC)
constitute the most abundant PL class, accounting for 58.9% of the PL pool (Table 4).
PC is the most abundant single PL sub-class accounting for more than half (52.8%) of the
entire PL pool. Ethanolamine phospholipids make the second most abundant PL class in
the cells, amounting to 25.1% of the PL pool. This class comprises PE-Pls,
phosphatidylethanolamine (PE) and lysophosphatidylethanolamine (LPE), contributing
13.1%, 11.6% and 0.4% to the PL pool, respectively. Plasmalogens (PE-Pls and PC-Pls)
account for 17.5% of the entire PL content. Besides being the second most prevalent PL
in the cells, PE-Pls are also the most abundant plasmalogen moieties, accounting for 75%
of the entire plasmalogen pool. Both choline and ethanolamine phospholipid classes
accounts for 82 % of the entire PL content of the cells. The cells also synthesize inositol
PLs containing phosphatidylinositol (PI) and lysophosphatidylinositol (LPI). Their
contribution to PL pool amounts to 7.5%.

Phosphatidylserine and sphingomyelin

constitute 3.2% and 3.3% of the pool, respectively.
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Figure 8. 31P NMR spectrum showing phospholipid profiles in N2A cells. 1. PC; 2. PC-Pls; 3.
AAPC; 4. U; 5. PI; 6. LPC; 7. PS; 8. SM; 9. PE; 10. PE-Pls; 11. LPI; 12. PG; 13. LPE; 14. U.
See abbreviations on pages Xiii – Xvi.
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Table 4. Phospholipid contents of N2A cells (Mean ± SE)
PL

PPM

nmol/mg protein

PL pool (%)

PC

-0.84

73.3 ± 9.0

52.8 ± 0.6

PE-Pls

0.12

18.3 ± 2.3

13.1 ± 0.4

PE

0.08

16.0 ± 1.9

11.6 ± 0.3

PC-Pls

-0.78

6.1 ± 0.8

4.4± 0.2

PI

-0.36

5.9 ± 0.7

4.3 ± 0.2

LPI

0.17

4.5 ± 0.6

3.2 ± 0.1

SM

-0.05

4.4 ± 0.5

3.3 ± 0.2

PS

-0.08

4.4 ± 0.5

3.2 ± 0.1

PA

0.25

1.6 ± 0.2

1.2 ± 0.1

LPC

-0.25

1.6 ± 0.2

1.2 ± 0.1

AAPC

-0.72

0.7 ± 0.1

0.5 ± 0.1

LPE

0.53

0.5 ± 0.1

0.4 ± 0.05

PG

0.51

0.4 ± 0.05

0.3 ± 0.02

U

-0.53

0.8 ± 0.2

0.6 ± 0.1

See abbreviations on pages Xiii – Xvi.
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4.1.2 Myo-inositol plus ethanolamine increases the levels of myo-inositol,
phosphoethanolamine, phospholipid pool and ethanolamine phospholipids in N2A
cells

Hoffman-Kuczynski and Reo (25, 155) have shown that rats treated with M plus
Etn have elevated PE-Pls levels by 30 % in whole brain relative to vehicle-treated
controls. In this study, we hypothesized that similar results can also be obtained in an
N2A cell culture system. We tested our hypothesis using four experimental groups that
involved culturing cells
in: (1) growth medium
(GM) only (control), (2)
GM supplemented with
500

M

myo-inositol

(M);

(3)

GM

supplemented with 500
M ethanolamine (Etn),

Figure 9. Schematic diagram of the experimental design
depicting times of treatments and analyses performed on
samples. C: Control (growth medium only); M: Myo-inositol

and

(4)

GM

(500 M); Etn: Ethanolamine (500 M); ME: Myo-inositol

supplemented with 500

(500 M) + Ethanolamine (500 M). See text for details and

M myo-inositol plus 500

abbreviations on pages Xiii - Xvi.

M ethanolamine (ME) for 24 h (Fig. 9A). The concentration of myo-inositol selected
was based on the findings from Novak et al. (185) who demonstrated that differentiated
human central nervous system neurons (NT2-N neurons) have a maximal velocity of
inositol uptake (Vmax) of 3.7 nmol/mg-protein/h when treated with various
concentrations of inositol ranging from 0 to 500 M. The concentration of ethanolamine
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was chosen based on the report showing that the maximum ethanolamine uptake for
neuronal cells is 41.4 pmol/mg-protein/min (186). A combination of myo-inositol plus
ethanolamine treatment (ME) was investigated since PE-Pls biosynthesis requires the
ethanolamine-derived CDP-ethanolamine in the pathway (86, 87), and our laboratory has
previously shown that this combination treatment leads to enhanced biosynthesis of
ethanolamine phospholipids in rat brain in vivo (25, 26, 155). The 24 h optimal
incubation time was determined in a separate series of experiments in which cells were
grown in growth medium supplemented with ME for 24, 48 and 72 h. The amounts of
PE-Pls (nmol/mg protein) obtained with these incubation times were not significantly
different (data not shown). Thus, we retained 24 h incubation time for the subsequent
experiments. NMR spectroscopy of cell lipid extracts provided a measure of phospholipid
composition. Phospholipids in each sample were normalized relative to protein level
assayed in an aliquot of cell extract (aqueous + lipid) using the bicinchoninic acid (BCA)
Protein Assay Kit (see Methods for details).
The effects of Etn, M and ME treatments on the cellular levels of myo-inositol are
illustrated by Fig. 10A. The treatments increased the cellular levels of myo-inositol in the
order: Etn < control < ME ~ M. Ethanolamine treatment alone did not have a significant
effect on myo-inositol level in the cells. However, both M and ME treatments induced a
3-fold increase (p < 0.05) in myo-inositol content of the cells relative to that in the
controls. Myo-inositol levels in these groups were also significantly higher (p < 0.05)
than that displayed by Etn treated group. The effect of Etn, M and ME on
phosphoethanolamine (PEtn) content of the cells was also determined. As shown in Fig.
10B, these treatments increased the cellular levels of PEtn in the order: control ~ M < Etn
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< ME. Etn mediated a 3.6-fold increase in PEtn levels in the cells relative to that obtained
with the control cells (p < 0.05). A robust increase in the cellular level of PEtn was
obtained with ME treatment relative to the control group (8-fold increase, p < 0.0001).
The level of PEtn in ME treated cells was also elevated (p < 0.01) in comparison to those
measured in M and Etn treated cells. M treatment had no significant effect on PEtn level
in the cells. These effects observed with Etn, M and ME on the cellular levels of myoinositol and PEtn were all expected.
We also investigated the effect of Etn, M and ME treatments on the PL pool in
N2A cells. As shown in Fig. 10C, Etn and M have no significant effect on the total PLs.
However, ME significantly enhanced the synthesis of PLs (2.4- fold increase, p = 0.0003)
when compared to the control group. The PL content in ME treated cells was also
significantly higher when compared to those in E and M groups (p = 0.0002 and p =
0.0009, respectively).
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Figure 10. Effect of myo-inositol, ethanolamine and myo-inositol plus ethanolamine treatments
on the level of (A) myo-inositol, (B) PEtn, (C) total PL, (D) PE-Pls and (E) PE in N2A cells
(Mean ± SE). Etn: ethanolamine (500 M) M: myo-inositol (500 M), ME: myo-inositol plus
ethanolamine (500 M each). Significant differences between groups are indicated by the letters:
a. differs from both control and Etn groups; b. differs from control and M treated groups; c.
differs from all groups; p  0.05. See abbreviations on pages Xiii – Xvi.
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We also determined the effects of myo-inositol and ethanolamine treatments on
the levels of ethanolamine plasmalogens (PE-Pls) in N2A cells. As displayed in Fig. 10D,
the treatments increased the cellular levels of PE-Pls in the order: control < Etn < M <
ME. Etn and M treatments alone did not significantly influence the level of PE-Pls in the
cells. Etn treated cells yielded a 21% increase in PE-Pls when compared to controls, but
this was not significant. M alone induced a 47% increase in PE-Pls level relative to the
control group, although this increase was not statistically significant due to the large
variance in the data. The greatest increase in PE-Pls level was obtained with cells treated
with ME (2.7-fold increase, p = 0.0008) when compared to controls. This was the same
treatment that yielded a significant increase in the cellular levels of both M and PEtn
(Fig. 10A & B). The PE-Pls content in this group was also significantly higher when
compared to those in Etn and M groups (p = 0.002 and p = 0.007 respectively). CDPethanolamine and 1-alkyl-2-acyl-sn-glycerol are part of the substrates required for the
biosynthesis of PE-Pls (5, 6, 39). PEtn is a substrate for ECT1 enzyme that catalyzes the
synthesis of CDP-ethanolamine in the Kennedy pathway (86, 87). It has been shown that
myo-inositol can be metabolized into dihydroxyacetone–3-phosphate (DHAP) (187, 188).
As DHAP is the first substrate required in the pathway leading to the biosynthesis of 1alkyl-2-acyl-sn-glycerol, it is probable that myo-inositol is upregulating this pathway.
Combining M and Etn in one treatment (ME) upregulates the pathways leading to the
synthesis of these two indispensable substrates that are required for the biosynthesis of
PE-Pls.
Effect of treatments on the PE level in N2A cells was also assessed since the
ethanolamine phosphotransferase (EPT), one of the enzymes involved in PE-Pls
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biosynthesis (Figure 4), is also required for PE synthesis. EPT combines CDPethanolamine and diacylglycerol to form PE. Thus, both EPT and CDP-ethanolamine are
required in PE and PE-Pls synthesis. As shown in Fig. 10E, the treatments increased the
cellular levels of PE in the order: control < M < Etn < ME. M and E groups yielded 23%
and 38% increases in PE contents of the cells, respectively, relative to control cells,
although these increases were not statistically significant (Fig. 10E). Interestingly, ME
treatment induced a 3-fold increase (p = 0.0003) in the cellular level of PE relative to the
control group. The PE level in ME group was also significantly elevated when compared
to those in Etn (p < 0.001) and M (p = 0.0007) groups. As shown in Fig. 10B, the
concentrations of PEtn were only elevated in E and ME treated cells when compared to
the controls. PEtn is a substrate for the ECT1 enzyme that catalyzes the synthesis of
CDP-ethanolamine in the Kennedy pathway (86, 87). These data indicate that both PE
and PE-Pls were increased only when a co-treatment (ME) was given. Although Etn
treatment increases PEtn level in the cells, Etn alone does not significantly elevate the
cellular content of PE and PE-Pls. This happens only when Etn is given together with M.
These data suggest that M given in a co-treatment (ME) may be positively affecting the
pathways leading to the production of diacylglycerol (required for PE synthesis) and 1alkyl-2-acyl-sn-glycerol (required for PE-Pls synthesis).
The effect of Etn, M and ME treatments on the cellular levels of other
phospholipid classes that do not carry ethanolamine as a head group was also investigated
in this study. As shown in Table 5, M and Etn treatments did not significantly influence
the levels of these PLs. However, it is noteworthy that Etn treatment displayed a trend by
negatively affecting the levels of the PL that have choline as a head group (PC, PC-Pls,
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LPC and AAPC). This was not surprising as it has been shown that ethanolamine exerts a
negative effect on the cellular uptake of choline (189). The levels of PC, LPC, PI, LPI,
PS and SM in the cells were significantly elevated (p  0.01) by ME at 24 h post
treatment when compared to controls. These data suggest that ME negated any effect that
Etn alone exerted on the levels of the choline phospholipids.
Currently, no clear description of the pathway for PC-Pls biosynthesis is available
(83, 190-192). However, it has been shown that PE-Pls is an essential precursor to PC-Pls
in neuronal cells (85). To get an insight on how each treatment affected the balance
between the levels of both plasmalogens in the cells, we calculated PE-Pls/PC-Pls ratio
for each group. Although the ratio in M treated cells (ratio = 4.4) was slightly increased
as compared to controls (ratio = 3.3), this increase was not statistically significant due to
the large variance in the data. However, this trend suggests that the rate of PE-Pls
synthesis was higher in M group relative to the control group. The PE-Pls/PC-Pls ratios
were significantly increased in both ME and Etn groups (ratio = 8.5 and ratio = 9.2
respectively) when compared to control. The higher ratio obtained with Etn group can
partially be justified by the observation that Etn treatment induced a slight decrease in
PC-Pls and an increase in PE-Pls levels. An elevated ratio obtained with ME can be
attributable to a strong increase (3-fold) in ME-mediated synthesis of PE-Pls in the cells.
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Table 5. Effects of M, Etn and ME treatments on PL in N2A cells (Mean ± SE)
PL (nmol/mg protein)
PPM

Control

M

Etn

ME

PC

-0.84

60.9 ± 18.4

69.0 ± 5.5

52.3 ± 3.6

130.8 ± 8.3

PC-Pls

-0.78

4.0 ± 1.1

4.9 ± 0.5

2.0 ± 0.2

4.1 ± 0.9

AAPC

-0.72

0.3 ± 0.1

0.4 ± 0.1

0.2 ± 0.05

0.6 ± 0.3

U

-0.53

0.7 ± 0.3

0.7 ± 0.1

0.4 ± 0.04

1.5 ± 0.2

PI

-0.36

4.7 ± 1.3

5.5 ± 0.7

4.9 ± 0.2

10.5 ± 1.8

LPC

-0.25

1.2 ± 0.3

1.2 ± 0.1

0.8 ± 0.1

2.4 ± 0.1

PS

-0.08

4.0 ± 1.3

4.0 ± 0.4

3.4 ± 0.3

8.8 ± 1.0

SM

-0.05

3.5 ± 0.8

4.5 ± 0.4

3.6 ± 0.3

9.9 ± 0.9

PE

0.08

13.8 ± 4.2

17.0 ± 2.2

19.1 ± 1.5

41.1 ± 5.8

PE-Pls

0.12

13.5 ± 3.7

19.8 ± 3.8

16.3 ± 1.1

36.6 ± 4.7

LPI

0.17

3.1 ± 0.9

4.3 ± 0.2

4.9 ± 0.3

12.9 ± 1.5

PA

0.25

1.0 ± 0.3

1.3 ± 0.2

1.1 ± 0.1

1.9 ± 0.6

PG

0.51

0.3 ± 0.1

0.3 ± 0.1

0.3 ± 0.03

0.8 ± 0.6

LPE

0.53

0.5 ± 0.2

0.5 ± 0.2

0.7 ± 0.1

1.9 ± 0.9

a. differs from all groups at p  0.05. See abbreviations on pages Xiii – Xvi.
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4.1.3 Cells treated with myo-inosiol plus ethanolamine show elevated ethanolamine
plasmalogens and are protected from H2O2-induced oxidative stress
To examine if increased ethanolamine phospholipids (in ME-treated cells) is also
protective against oxidative stress, we used hydrogen peroxide (H2O2) as an oxidative
stress-inducing agent. H2O2 has
been used in various studies to
induce oxidative stress in the
cells (161-164). Studies have
Figure 11. Fenton and Haber-Weiss reaction. A reduced

provided

evidence

that

form of a transition metal (M𝑛) reacts through the

extracellular H2O2 can cross the

Fenton reaction with hydrogen peroxide (H2O2), leading

cell membrane through specific

also react with the oxidized form of transition metals

aquaporin channels (193-195).

(M(𝑛+1)) in the Haber-Weiss reaction leading to the

to the generation of ∙OH. Superoxide radical (O2∙−) can

production of M𝑛, which then again affects redox

The mechanisms through which

cycling [129].

H2O2 induces oxidative stress in the cells have also been described (196, 197). This
involves the generation of hydroxyl radical, a highly reactive molecule (131) through the
redox cycling by Fenton reaction (129, 198) (Fig. 11).
To determine a concentration of H2O2 that leads to approximately 50% cell death
in 24 h, cells were cultured in the growth medium alone (control) or medium
supplemented with H2O2 ranging from 0 to 2000 M (0, 300, 400, 500, 600, 650, 800 and
2000 M) for 24 h. Cell viability was assessed using trypan blue assay. This assay has
also been used by other investigators to determine cell viability to different cell stressors
(199-201). As illustrated in Fig. 12A, a concentration of 650 M H2O2 yielded 53 ± 1.4%
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(n=7) cell viability relative to control cells. This concentration was retained for
subsequent experiments. The experimental design for these studies is shown in Fig. 9A.
N2A cells were pre-treated with GM only (control; C), or medium supplemented with
Etn, M, or ME for 24 h to increase the cellular level of Etn phospholipids. At 24 h, cells
were rinsed with phosphate buffered saline (PBS) and incubated in fresh medium
(control) or medium supplemented with 650 M H2O2 for an additional 24 h (see
methods for details). Each experimental group had its own control that did not receive
H2O2. Cell viability then was assessed using trypan blue assay kits. The percent cell
viability in each group was measured relative to its corresponding control group set to
100%. As illustrated in Figure 12B, exposure to 650 M H2O2 for 24 h yielded 55.9 ±
1.1% (n = 16; p ≤ 0.0001) cell viability relative to corresponding control cells (n = 16).
Pretreatment of cells with Etn alone (n = 5) did not protect cells against H2O2 toxicity (53
± 1.4% cell viability; n = 5), but pretreatment with M increased cell viability significantly
(62 ± 1.2%; n = 5; p = 0.0004), while ME treatment provided the greatest cell protection
(79.5 ± 0.6%; n = 13; p ≤ 0.0001). These data suggest that M pretreatment can protect
N2A cells from H2O2-induced oxidative damage, but a greater protection is obtained
when the cells are pretreated with ME. ME is the same treatment that yielded a 2.7-fold
increase in PE-Pls (Fig. 10D) and a 3-fold increase in PE (Fig. 10E) and also an increase
in other non-ethanolamine lipids as shown in Table 5. It is interesting to note that the
levels of PE-Pls in the cells prior to H2O2 treatment highly correlate (r2 = 0.95) with the
cell viability following this treatment (Fig. 12C). However, the concentrations values for
PE-Pls used to run this correlation analysis were obtained from the measurements made
at 24 h post ME treatment, prior to H2O2 exposure. Assessment on cell viability was
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made at 24 h post H2O2 exposure (48 h post ME treatment). Thus, both measurements
were not made from the same group of cells, but these cells were from the same batch.

Figure 12. N2A viability by trypan blue assay (Mean ± STDEV) (A) after exposure to H2O2 for
24 h at concentrations ranging from 0 – 800 M. Data are normalized to the control group set at
100%. Sample size is n=1 at each concentration except at 500 M (n=3), 600 M (n=4), and 650
M (n=7). A measurement was also made at 2,000 M H2O2 yielding 2% cell viability (data not
shown). (B) on cells pre-treated with growth medium only, myo-inositol, ethanolamine, myoinositol plus ethanolamine for 24h followed by an exposure to 650 M H2O2 yielding for 24h.
Assessment of cell viability in each treatment group is relative to a corresponding control group
(set at 100%) that received the pre-treatment, but not H2O2. Sample size is n = 16 (H2O2), n = 5
(Etn + H2O2), n = 5 (M + H2O2); n = 13 (ME + H2O2). (C) Correlation between PE-Pls level and
neuroprotection. Cell viability assays and measurements on concentrations of PE-Pls were carried
out on different batches of cells. See text for details. (D) Apoptosis on cells pre-treated as
described in (B). The letter “a” denotes significant differences (p < 0.05) from H2O2 group,
whereas “b” refers to significant differences from all the other groups. See abbreviations on pages
Xiii – Xvi.
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4.1.4 Myo-inositol plus ethanolamine blocks the H2O2-mediated decrease in
ethanolamine plasmalogens in N2A cells

It has been suggested that the vinyl ether bond of plasmalogen is highly sensitive
to oxidation (15-20, 145, 146) and may be involved in cell protection against oxidative
stress (149, 150). Evidence that PE-Pls may be associated with cell protection is
supported by the following observations: (1) treating N2A cells with ME yielded a 2.7fold increase in PE-Pls content (Fig. 10D); (2) exposing these ME pretreated cells to
H2O2 for 24 h resulted in a significant increase in cell viability (Fig. 12B); (3) cell
viability and the level of PE-Pls are positively correlated (Fig. 12C); (4) previous studies
in rats in vivo have shown protection against oxidative damage in brain regions where
PE-Pls content is elevated (26, 146); and (5) the vinyl ether bond of PE-Pls is more prone
to oxidation than ether or ester linkages (1). Therefore, we hypothesize that an increase in
cell survival to H2O2-induced oxidative damage following ME treatment (79.5% cell
viability, Fig. 12B) in the current study is a result of PE-Pls acting as a sacrificial trap of
ROS, thus quenching oxygen free-radical propagation and shielding other crucial cellular
molecules from oxidation. Consequently, we believe that by pre-treating the cells with
ME, we enhanced the baseline level of PE-Pls in the cells, which served as ammunition
stock that cells depended on when they were facing excessive oxidative stress. This
hypothesis was tested using an experimental design that involved (1) pre-treating the cells
with the growth medium only (C) or ME for 24 h to increase the level PE-Pls in the cells,
(2) at 24 h, rinsing cells with PBS and incubating them in fresh medium (control) or
medium supplemented with 650 M H2O2 for an additional 24 h (Fig. 9B) and (3)
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assessing the impact of H2O2 on the PL profile, with a special interest in PE-Pls (see
methods for details).
As shown in Fig. 13A and 13B, the levels of myo-inositol and PEtn in N2A cells
were significantly increased by incubating cells in growth medium supplemented with
ME over a 24 h period when compared to controls. However, the level of these
metabolites returned to baseline (corresponding control values) after removing the growth
medium that contained ME and re-suspending the cells in fresh growth medium for an
additional 24 h period. The level of PEtn in ME group significantly decreased from 154
nmol/mg protein (at 24 h) to 49 nmol/mg protein (at 48 h) while the myo-inositol level
decreased from 10 nmol/mg protein to 7 nmol/mg protein. H2O2 treatment had no
significant effect on the levels of these metabolites. However, myo-inositol content in ME
+ H2O2 treated group showed a trend of further decreasing when compared to its control
(ME), suggesting a role for myo-inositol in cell protection, possibly via an increase in its
utilization for the synthesis of new PE-Pls. We also assessed the PL level in the cells
treated with ME for 24 h and exposed to H2O2 for an additional 24 h (Fig. 13C).
Stopping the ME treatment did not affect the cellular content of PL pool. The level of PL
pool remained significantly elevated (p = 0.04) in the ME group relative to controls (both
untreated controls and corresponding ME-treated controls). Although the H2O2 treatment
did not statistically influence this pool, cells pre-treated with ME and dosed with H2O2
displayed an increasing trend in PL content when compared to corresponding controls
(ME).
As shown in Fig. 13D, ME increased the PE-Pls levels at 24 h (36.6 ± 4.7
nmol/mg protein) by 2.7-fold (p = 0.0008) in comparison to the control group. This level
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was not significantly different from that measured at 48 h (33.8 ± 2.9 nmol/mg protein,
24 h after stopping ME treatment). At 48h, however, the PE-Pls content in ME group was
still significantly elevated (p = 0.005) relative to that measured in the control group (at 48
h). Cells pre-treated with growth medium only and exposed to H2O2 for 24 h (H2O2
group) displayed a 13% decrease in PE-Pls level when compared to corresponding
control, although the decrease was not significant. Interestingly, this effect associated
with H2O2 treatment was not observed in the cells that were pretreated with ME (ME +
H2O2 group). In fact, the PE-Pls content in this group was increased by 8% when
compared to corresponding control (ME). The treatments affected the levels of PE-Pls in
the order: H2O2 < control < ME < ME + H2O2.
We also assessed the impact of exposing cells to H2O2 on the cellular level of PE.
As shown in Fig. 13E, ME treatment elevated the PE levels, yielding a 3-fold increase (p
= 0.0001) at the end of ME treatment (41.1 ± 5.8 nmol/mg protein at 24 h) as compared
to that measured in the control group. The PE content dropped to 32.3 ± 2.8 nmol/mg
protein at 48 h after stopping the ME treatment, although this decrease was not
statistically significant (p = 0.09). However, this level (32.3 ± 2.8 nmol/mg protein) was
significantly higher (p = 0.001) when compared to the corresponding control group (17.3
nmol/mg protein) at 48 h. Contrary to the observation that the cellular level of PE-Pls in
the H2O2 group decreased by 13%, it is interesting to note that these cells displayed a 3%
higher PE level relative to corresponding control, although this increase was not
significant. These data suggest that PE-Pls were more sensitive to H2O2-induced
degradation than PE species. The PE content in ME + H2O2 group increased by 17%

56

relative to that measured in ME group. The levels of PE measured in these experimental
groups were in the order: control < H2O2 < ME < ME + H2O2.

Figure 13. Effects of H2O2 treatment on the level of (A) myo-inositol, (B) PEtn, (C) PL pool, (D)
PE-Pls and PE in N2A cells (Mean ± SE). Significant differences between groups are indicated
by the letter: a. differs from control group; p  0.05. See abbreviations on pages Xii - Xiii.

As shown in Table 5, the cellular levels of PC, LPC, PI, LPI, PS and SM were
significantly elevated by ME at 24 h post treatment when compared to controls. It is also
interesting to note that 24 h after stopping ME treatment (measurements taken at 48h),
the levels of these PLs were similar to controls, except LPI and SM which remained
significantly higher (p  0.01) (Table 6). H2O2 treatment did not significantly affect the
level of these PLs (Table 6). In ME + H2O2 group, the cellular contents of these
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phospholipids were also similar to those in the corresponding control (ME group) except
the levels for PS and AAPC which were significantly elevated (p < 0.02).
Table 6. Effects of H2O2 treatment on phospholipids in N2A cells (Mean ± SE)
PL (nmol/mg protein)
PPM

Control

H2O2

ME

ME + H2O2

PC

-0.84

80.3 ± 9.7

75.3 ± 10.9

104.5 ± 8.6

122.3 ± 7.8

PC-Pls

-0.78

7.3 ± 1.0

7.2 ± 1.3

3.6 ± 0.4

5.5 ± 0.7

AAPC

-0.72

0.9 ± 0.1

1.1 ± 0.2

0.6 ± 0.1

1.1 ± 0.2

U

-0.53

0.8 ± 0.2

1.0 ± 0.2

1.1 ± 0.2

1.3 ± 0.2

PI

-0.36

6.5 ± 0.8

5.7 ± 0.6

7.4 ± 0.8

8.6 ± 0.7

LPC

-0.25

1.9 ± 0.1

1.4 ± 0.2

1.9 ± 0.1

2.1 ± 0.2

PS

-0.08

4.6 ± 0.4

4.9 ± 0.7

5.1 ± 0.5

7.1 ± 0.5

SM

-0.05

4.9 ± 0.6

4.4 ± 0.6

7.8 ± 1.0

PE

0.08

17.3 ± 1.9

17.8 ± 2.4

32.3 ± 2.8

PE-Pls

0.12

21.0 ± 2.6

18.3 ± 2.8

33.8 ± 2.9

LPI

0.17

5.4 ± 0.7

6.2 ± 0.8

8.8 ± 0.6

PA

0.25

2.0 ± 0.1

1.8 ± 0.3

2.2 ± 0.3

2.5 ± 0.3

PG

0.51

0.4 ± 0.1

0.3 ± 0.1

0.6 ± 0.2

0.6 ± 0.1

LPE

0.53

0.5 ± 0.1

1.1 ± 0.2

1.1 ± 0.2

1.4 ± 0.2

a

a
a
a

a

b

b

7.6 ± 0.7
37.8 ± 2.8
36.4 ± 2.4
10.7 ± 0.7

a. Differs from control; b. differs from ME group, p < 0.05. See abbreviations on pages Xiii - Xvi
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4.1.5 Myo-inositol plus ethanolamine blocks the H2O2-mediated increase in lysoethanolamine lipids and glycerophosphoethanolamine in N2A cells

In order to gain more insight on how H2O2 treatment affected ethanolamine
phospholipids, we measured the levels of the degradation by-products of PE and PE-Pls
by NMR. These included lysoglycerophosphoethanolamine (LPE) that is derived from
hydrolysis of an acyl chain at the sn-1 (1-lyso) or sn-2 (2-lyso) position of the glycerol
backbone of PE and PE-Pls. The 2-lyso species generated from PE and PE-Pls are
structurally different. The 2-lyso that is from PE-Pls hydrolysis has an acyl chain attached
via a vinyl ether linkage at the sn-1 carbon. The 2-lyso, derived from PE, has an acyl
chain attached via an ester bond at the sn-1 carbon. The 1-lyso compounds derived from
PE-Pls and PE may have similar chemical structures if the acyl chains attached to sn-2
are similar. Their structure will be different if these acyl chains are chemically different.
In this study, LPE represents a mixture of all these lyso species since they all give rise to
a single peak in
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P NMR spectrum. The source of GPE includes the hydrolysis of both

acyl chains in PE and PE-Pls or the removal of the acyl chain from LPE. Since both PE
and PE-Pls contributed to LPE and GPE in our samples, we assessed the effect of
treatments on LPE by calculating the ratio of the by-product to its precursors [(LPE/(PE +
PE-Pls)] in each sample and comparing the ratio and GPE level across the treatment
groups (Fig. 14A and 14B). The LPE/(PE + PE-Pls) ratio at 24 h post ME treatment did
not differ from that calculated for the control group (Fig. 14A). These ratios were also
not statistically different 24 h after stopping ME treatment (measured at 48 h). In
contrast, the H2O2 group yielded a LPE/ (PE + PE-Pls) ratio that was 3.2-fold (p = 0.005)
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higher in comparison to control, suggesting that there was a H2O2-induced increase in
LPE level and a decrease in PE and PE-Pls levels in the cells.

Figure 14. Effects of H2O2 treatment on the level of (A) LPE and (B) GPE in N2A cells (Mean ±
SE). Significant differences between groups are indicated by the letters: a. differs from control
group; b. differs from ME treated group; p  0.05. See abbreviations on pages Xiii - Xvi.

Our data show that PE-Pls level for the H2O2 group was decreased by 13% (Fig.
13D) while that of PE was increased by 8% (Fig. 13E), suggesting that an increase in
LPE production in this group is predominately attributable to PE-Pls degradation. The
LPE/(PE + PE-Pls) ratio for ME + H2O2 group was similar to that calculated for its
corresponding control (ME), suggesting that ME treatment blocked the H2O2-mediated
degradation of PE-Pls. The GPE level at 24 h post ME treatment was similar to that
measured for the control group (Fig. 14B). These metabolites were also not statistically
different 24 h after stopping ME treatment. In contrast, the GPE level for H2O2 group was
increased by 4-fold (p = 0.003) when compared to control, suggesting a H2O2-induced
increase in GPE production and a decrease in PE and PE-Pls degradation in the cells.
Since the PE-Pls levels for the H2O2 group displayed a decrease while that for PE showed
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an increase, the data suggests that an increase in GPE in this group is predominately
attributable to PE-Pls degradation. Surprisingly, the GPE level for the cells pre-treated
with ME was not affected by H2O2 treatment when compared to its corresponding control
(ME) (p = 0.5). This suggests that ME treatment blocked the H2O2-mediated degradation
of ethanolamine phospholipids.
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4.2 DISCUSSION
4.2.1 Phospholipid profiles in N2A cells

The current study was conducted to (1) characterize the phospholipid profiles of
N2A cells, (2) investigate the impact of myo-inositol alone, ethanolamine alone and myoinositol plus ethanolamine (ME) treatments on the PL profiles in N2A cells, with a
special interest in ethanolamine phospholipids, (3) determine how these treatments affect
the cell’s ability to respond to H2O2-induced oxidative stress, and (4) determine how
H2O2 affects the cellular contents of PL, with a special interest in ethanolamine
phospholipids.
Although N2A cells have been extensively used to study various biological
processes (14, 156, 202-205), their phospholipid compositions have not yet been
reported. We therefore characterized the PL profile of the cells as shown in Table 4.
These cells synthesize different PL classes. It is worth noting that we were not able to
measure the levels of AAPE species by NMR but we were able to measure them by mass
spectrometry. It has been reported that the central nervous system is predominantly rich
in PE-Pls and PE and poor in AAPE moieties (206). AAPE species gets converted into
PE-Pls by delta-1-alkyl-desaturase enzyme when it inserts a double bond between C1 and
C2 of its alkyl chain (Fig. 4) (6). Two possibilities may explain why we were unable to
detect AAPE species by NMR. First, it could be that these species were much lower in
concentrations, thus, yielding very weak peak intensities below the level of detection.
The other possibility is that they accumulated to an appreciable concentration, but the
resonance was buried under the tall and broad peaks for PE-Pls and PE. AAPE, PE-Pls
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and PE have structural similarities and the only feature that distinguish them is the
linkage of their acyl chains at sn-1 position to the glycerol backbone (ether, vinyl ether
and ester linkages for AAPE, PE-Pls and PE, respectively).
Plasmalogens are the major phospholipid constituents of the neural membranes
(55). PE-Pls and PC-Pls are the only vinyl ether linked species synthesized by these cells.
PE-Pls are three times more abundant (18.3 ± 2.3 nmol/mg protein) than PC-Pls (6.1 ±
0.8 nmol/mg protein). These are the two major plasmalogens species that have been
reported to be the constituents of the mammalian cell membranes (55). PE-Pls are the
most dominant plasmalogens in most cells, except in skeletal and cardiac muscle where
PC-Pls is prevalent (55). PE-Pls accounted for 13.1% of the total PL pool, and 54% and
75% of the ethanolamine lipids and plasmalogen pool, respectively. Comparing the
phospholipid compositions of N2A cells to those for mixed murine spinal cord neuronal
cultures (207), the spinal cord cells contribute fewer amounts of choline
glycerophospholipids

(43.5%),

but

a

higher

amount

of

ethanolamine

glycerophospholipids (44.8%) to the PL pool. The contribution of PE-Pls to this pool
(13.0%) is consistent with what we measured in N2A cells (13.1%). However, in spinal
cord cells, PE-Pls are a smaller fraction of total ethanolamine phospholipids (29.1%)
compared to that recorded with N2A cells (54%). Likewise, N2A cells contain greater
amounts of PC-Pls (4.4%, compared to 1.9%) and PI (4.3%, compared to 1%), but more
comparable amounts of PS (3.2%, compared to 2.5%) and SM (3.3%, compared to 2.9%)
than those measured in spinal cord cells. The spinal cells, however, have higher levels in
PE (25.9%, compared to 11.6%), AAPC (3.6%, compared to 0.5%), and LPE (1.5%
compared to 0.4%) than those measured in N2A cells. Two possible reasons may explain
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the differences in phospholipid compositions between these two cell cultures. First, the
differences may result from alterations in phospholipid metabolism inherent to different
culture conditions. Second, we cannot also rule out the possibility that differences may
derive from tissue sources of the cells. Pertinent questions that our dataset does not
provide answers to are (1) how the phospholipid compositions in N2A cell culture system
reflect those generated from in vivo settings, and (2) how they relate to those in human
neurons. It has been shown that PE-Pls are the most abundant plasmalogens in human
brain (5) with an abundance ranging between 15 and 20% of the PL pool in the cell
membranes (5). The level of PE-Pls in N2A cells (13.1%) is comparable.
Studies have suggested that plasmalogens may possess antioxidant properties,
protecting the cells against oxidative damage (12, 15, 40, 146). This is partially due to
their vinyl ether linkage at the sn-1 position of the glycerol backbone that may be more
susceptible to oxidation than the corresponding ester bond in other glycerophospholipid
moieties (16, 18, 40, 208). If plasmalogens are potentially serving as antioxidants in the
cells, then establishing the mechanisms that can increase their cellular baseline levels will
be beneficial against excessive oxidative stress. In this regard, studies have shown that
myo-inositol increases the levels of PE-Pls in rat brain (25, 26, 155, 209) and in serum
for hyperlipidemic patients with metabolic syndrome (46). A systemic administration of
PE-Pls can abolish the lipopolysaccharide-induced neuroinflamation and -amyloid
protein accumulation in the mouse brain (10, 11). All these studies have been conducted
in vivo, where the system is more complex to pinpoint exactly the source of plasmalogens
measured in these tissues. Reactive oxygen species (ROS) and a deficiency in cellular
plasmalogen levels have been implicated in neuronal cell death and pathogenesis of
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neurodegenerative diseases (21, 22, 24, 111, 117, 123, 124, 210-213). There is an urgent
need for designing neuroprotective interventions that can stop or reverse the ROSmediated progression of neuronal death. If plasmalogens possess the antioxidant
properties as studies have suggested (12, 15, 40, 146), then increasing their levels in
neuronal cells may be a potential intervention mechanism that can slow, stop or rescue
cells from ROS-induced death. Thus, this could reverse the course of diseases/disorders
by stopping or slowing its progression.
In the current study, our goal was to determine if treating N2A cells with myoinositol +/- ethanolamine would increase levels in ethanolamine phospholipids, especially
PE-Pls. We hypothesized that a co-treatment (ME) would elevate the levels of these
phospholipids, possibly via enhanced biosynthesis. ME would yield more PE-Pls since
the biosynthesis of these species requires ethanolamine-derived CDP-ethanolamine
(Kennedy pathway) (87), and our laboratory has previously shown that this combination
treatment leads to enhanced biosynthesis of ethanolamine phospholipids in rat brain in
vivo.
Myo-inositol is an essential organic osmolyte molecule found in brain, kidney and
retina (214). In brain and cerebrospinal fluid, its levels increase with age (215). Humans
obtain myo-inositol from the diet such as fruits, vegetables, and wheat germ. The daily
dietary intake ranges between 500 mg to 2000 mg (46). The body can also make it
through de novo synthesis that requires glucose 6-phosphate as the first substrate (216).
Myo-inositol plays an essential role in eukaryote cells, where it is used in various
biological processes such as the synthesis of phosphatidylinositol (217), a known
structural neural membrane component serving as a precursor for inositol-containing
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membrane phospholipids such as glycerophosphoinositol and a wide variety of the
membrane-bound signaling molecules as well as the soluble second messengers (218220). Our data show that the concentration of myo-inositol in N2A cells was 3.6 nmol/mg
protein (Fig. 10A). Ethanolamine treatment alone did not influence the level of myoinositol in the cells. However, both M and ME treatments induced a 3-fold increase (p <
0.05) in the cellular level of myo-inositol relative to that in the control group. This
increase was reversed by removing the medium that contained ME and re-suspending the
cells in fresh medium for an additional 24 h (Fig. 13A). Some literature reports indicate
that the concentrations of myo-inositol in rat brain range between 6 – 8 mol/mg tissue
(155, 221, 222), while others report that concentrations vary between 2 - 4 mol/mg
tissue (223). Although these discrepancies exist on the actual cellular levels of myoinositol, there seems to be a common agreement that ethanolamine alone does not impact
the cellular levels of myo-inositol. Hoffman and Reo (155) have also shown that myoinositol and ethanolamine do not elevate the cellular levels of myo-inositol in rat brain
unless they are given together as a co-treatment.
As expected, only ethanolamine and ME treatments increased the levels of PEtn
in N2A cells. In fact, a 3.6-fold increase was observed in ethanolamine treated cells
relative to the controls (p < 0.05). The increase was even more robust (8-fold increase, p
 0.0001) for the cells treated with ME relative to control cells. The level of PEtn in the
ME group significantly decreased after removing the medium that contained ME and resuspending the cells in fresh medium for an additional 24 h period (Fig. 13B). Marshall
et al. (224) have also investigated the effect of exogenous ethanolamine on its
concentrations in arterial plasma, brain extracellular fluid and the whole brain of rats.
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Their findings indicated that ethanolamine treatment increased its levels in these tissues
and fluid in a dose-dependent fashion. Ethanolamine is an indispensable molecule in the
Kennedy pathway (87) for the synthesis of CDP-Ethanolamine, a substrate required for
de novo synthesis of both PE-Pls and PE (6, 87).

Myo-inositol alone and ethanolamine

alone did not have a significant impact on the levels of PL pool, PE-Pls and PE in N2A
cells (Fig. 10C, D & E). Myo-inositol and ethanolamine elevated the cellular contents of
PE-Pls by 47% and 21%, respectively. They also increased the levels of PE by 23% and
38%, respectively. Only co-treating cells with both myo-inositol and ethanolamine (ME)
yielded a significant increase in the total PL pool (2.2-fold), PE-Pls (2.7-fold) and PE (3fold) relative to the control group. The levels of PL pool, PE-Pls and PE remained
significantly elevated (p = 0.005) after replacing the growth medium that contained ME
with fresh growth medium for an additional 24 h. It is also noteworthy that the levels of
myo-inositol and PEtn dropped and were similar to those measured in the control group,
suggesting they were actively being used to sustain the levels of these phospholipids.
Although it is not clear how ME influenced the PL levels in N2A cells, a possible
explanation for PE-Pls and PE could be that myo-inositol and ethanolamine provided
substrates required for their synthesis. It has also been suggested that the effect of myoinositol on PE-Pls levels may be associated with an increase of NADPH since its
catabolism through the pentose phosphate cycle yields 2 molecules of NADPH (55). It is
well established that myo-inositol can be metabolized into dihydroxyacetone-3-phosphate
(DHAP) via the pentose phosphate pathway. DHAP is the first substrate required in the
peroxisome for de novo synthesis of PE-Pls (6). From our data, it is possible that myoinositol influenced the level of PE-Pls by increasing the cellular content of peroxisomal
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DHAP available to the PE-Pls pathway. In PE-Pls synthesis pathway, 1-alkyl-2-acylglycerol combines with CDP-ethanolamine (metabolized from ethanolamine) (see Fig. 4)
to form 1-alkyl-2-acyl-GPE. Then, 1-alkyl-2-acyl-GPE is converted into PE-Pls by a
desaturase enzyme. Therefore, the importance of PEtn (ethanolamine metabolite) for the
synthesis of PE-Pls is understandable. Similarly, the CDP-Etn can also combine with
diacylglycerol to form PE. Other studies that have investigated the effect of myo-inositol
with or without ethanolamine on the PL contents in rat brain (25, 155) reported a 47%
increase in newly synthesized ethanolamine phospholipids in the whole rat brain and an
89% increase in the cerebellum region following ME treatment. Additionally, they also
observed a 30% increase in PE-Pls in the cerebellum region of the rat brain following this
treatment. Our findings are in agreement with Hoffman-Kuczynski and Reo’s reports (25,
26, 155) which show that the co-treatment of ME is an essential recipe for increasing PEPls levels in rat brain.
We also investigated the effect of myo-inositol, ethanolamine and ME treatments
on the other phospholipid classes. As shown in Table 5, myo-inositol and ethanolamine
treatments did not significantly influence the levels of these PLs. However, it is
noteworthy that ethanolamine treatment displayed a trend in negatively affecting the
levels of choline-containing PL (PC, PC-Pls, LPC and AAPC). However, this effect was
not observed when ethanolamine was given together with myo-inositol, suggesting that
ME negated any effect that ethanolamine alone exerted on the levels of the choline
phospholipids. The effect of ethanolamine on choline phospholipids was not surprising as
it has been shown that ethanolamine exerts an inhibitory effect on the cellular uptake of
choline (189). We also observed a significant increase (p  0.01) in the levels of PC,
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LPC, PI, LPI, PS and SM for the cells that were treated with ME for 24 h relative to the
controls. It is also worthy to note that 24 h after stopping ME treatment and incubating
them in fresh growth medium for an additional 24h, their contents in these PLs were
similar to those in the controls, except for LPI and SM levels, which remained
significantly elevated (p  0.01; Table 5).

4.2.2 Myo-inositol plus ethanolamine protects N2A cells against H2O2-induced
oxidative stress

It is interesting to highlight that the levels of PE-Pls in the cells prior to H2O2
treatment highly correlate (r2 = 0.95) with the cell viability following this treatment (Fig.
12C). This suggests that increasing the baseline level of PE-Pls can help the cells cope
with oxidative stress. However, the mechanism behind this protection is not known. H2O2
is classified as an oxidant with the potential to inflict damage to nucleic acids, proteins,
as well as lipids (193). Studies have provided evidence that extracellular H2O2 can cross
the cell membrane through specific aquaporin channels (193-195). The intracellular H2O2
concentration is tightly controlled (193). Mechanisms through which H2O2 induces
oxidative stress in the cells have been described (196, 197). It has been reported that
H2O2 itself is not a very potent harmful agent to the cells (194), but can easily get
metabolized into the highly reactive hydroxyl radical molecule (·OH) via the Fenton
reaction (198) and this moiety can oxidize lipids, nucleic acids and proteins (194). Our
data clearly show that pre-treating N2A cells with ME prior to H2O2 exposure
significantly limits the H2O2-mediated N2A cell death (79.5 ± 0.6% cell viability) as
compared to the control cells (55.9 ± 1.1% cell viability). Hardaway et al. (160)
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investigated the N2A cells viability to ascorbic acid and H2O2 and reported that exposing
these cells up to 300 M H2O2 does not produce a significant cell death. At a dose of 300
M, they recorded 92.0 ± 4.3% cell viability. The highest dose of H2O2 that was used in
their study was 400 M, which significantly reduced the cell survival to 73 ± 4.3%. The
estimated LC50 was determined to be above 400 M H2O2. In the current study, the cell
viability at 300 M and 400 M H2O2 are 89% (n = 1) and 82% (n = 1), respectively.
Thus, data for Hardaway et al. (160) and ours are very similar. Cells pre-treated with ME
prior to H2O2 exposure tolerate 650 M H2O2 like control cells treated with 400 M
H2O2. Although the mechanisms of ME-induced cell protection have not yet been
elucidated, it is possible that the protection may be linked to changes in the cellular levels
of ethanolamine phospholipids such as PE-Pls mediated by this treatment (Figs. 10D &
E). This is also supported by the observation that levels of PE-Pls in the cells prior to
H2O2 treatment highly correlate (r2 = 0.95) with cell viability following H2O2 exposure
(Fig. 12C). Hossain et al. (13) have shown that plasmalogens (consisting of 96.5%
ethanolamine plasmalogens and 2.5% choline plasmalogens) are capable of rescuing
N2A from serum starvation-induced apoptosis. They treated N2A cells with 10% FBS
(fetal bovine serum), 0.4% FBS and 0.4% FBS plus a mixture of plasmalogens
(consisting of 96.5% ethanolamine plasmalogens and 2.5% choline plasmalogens) at
concentrations of 5 μg/ml and 20 μg/ml for 72 hours and determined the cell survival rate
and the activity of caspases involved in serum starvation-induced apoptosis. Their data
demonstrate that plasmalogen concentrations of 5 μg/ml and 20 μg/ml significantly
increased cell survival and enhanced phosphorylation of AKT and ERK 1/2, which are
known to inhibit the cleavage of pro-apoptotic caspase-9 and caspase-3 (157-159). Our
70

data show that 650 M H2O2 induced a significant decrease in apoptosis, while this effect
was not observable in the cells pre-treated with ME prior to being exposed to this dose of
H2O2. It has been shown that a moderate dose of H2O2 can trigger apoptosis, whereas an
elevated dose induces necrotic cell death (225-227). For example, when T-lymphoma
cells are treated with a dose of H2O2 that is equal or less than 300 M for 6 h they display
activation of caspase-9 and caspase-3 activity, resulting in apoptotic cell death (228-230).
However, when these cells are exposed to 500 M H2O2 for 6 h, they don’t display
caspase activity and they die from necrosis (230). In the current study, N2A cells also
responded to a dose of 650 M H2O2 by decreasing apoptosis. This effect was not
observed with ME + H2O2 treatment. In fact, the level of apoptosis was similar to that
observed in the corresponding control (ME), suggesting that ME decreased necrosis. It
has been reported that a lower concentration of H2O2 temporally inhibits the caspases
enzymes, giving the cells the possibility to repair them for the apoptosis to resume (229).
However at a higher dose of H2O2, the caspases remain inhibited, resulting in necrosis
event (229). Caspase enzymes are sensitive to an increase in ROS and the cell must
maintain an intracellular reducing environment for apoptosis to proceed (229). This
suggests that ME+ H2O2 may be providing this environment, thus preventing cells from
undergoing necrosis.
It has been suggested that the vinyl ether bond of plasmalogens is highly sensitive
to oxidation than ether or ester linkages (16, 18, 40, 208, 231) and may be involved in
cell protection against oxidative stress (12, 15, 40, 146). Although we cannot draw
conclusion on the involvement of PE-Pls species in N2A cell protection against H2O2induced oxidative damage, our data suggest that these species may be among the targets
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since their levels decreased following H2O2 exposure. Interestingly, the cellular levels of
PE were not decreased by H2O2 treatment. The mechanism by which ME treatment
blocked the H2O2-induced decrease in PE-Pls levels in the cells is unclear and requires
further investigation. The significance of PE-Pls in neuropathologies is highlighted by
findings that neurodegenerative disorders/diseases are associated with a decrease in PEPls levels (23, 24, 119). However, it remains to be elucidated if a decrease in PE-Pls is a
contributing cause or downstream effect of pathology of these diseases/disorders (232).

4.2.3 Myo-inositol plus ethanolamine blocks the H2O2-induced degradation of
ethanolamine phospholipids

In order to get more insight on how H2O2 treatment affected ethanolamine
phospholipids, we measured the levels of the degradation by-products (LPE and GPE) of
PE and PE-Pls. Since ME treatment enhanced the PE-Pls levels and increased the cell
viability (80%) following H2O2-induced oxidative damage, we expected a decrease in
PE-Pls and an increase in both LPE and GPE levels if PE-Pls were being sacrificed.
Thus, not observing these effects was a surprising outcome. LPE can give rise to GPE
when the remaining acyl chain is hydrolyzed. Lysoplasmalogenase enzyme also known
as alkenyl ether hydrolase (alkenylglycerophosphoethanolamine hydrolase) hydrolyzes
lysoplasmalogens to yield GPE (233-235). This enzyme is highly specific for
glycerophospholipids containing a vinyl-ether linkage at sn-1 and a hydroxyl (lyso) at sn2, and acts with nearly equal efficiency on ethanolamine and choline classes (236). It is
possible that H2O2 has an effect on the activity this enzyme and that effect was inhibited
by ME treatment. The other possible explanation for these results is that the cells
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preserve homeostasis through balancing PE-Pls degradation and synthesis/remodeling.
The level of myo-inositol in this group dropped to the level below that of the control
(ME), suggesting that it was actively being utilized, presumably for the synthesis of PEPls. In the neural membranes, the homeostasis of plasmalogens is controlled by a balance
that must exist between their degradation, de novo synthesis and re-synthesis (reacylation/de-acylation cycle) (52). We therefore cannot rule out the possibility that 1alkenyl-2-lyso-GPE (lyso-plasmalogens) were re-acylated to form new PE-Pls, while the
1-acyl-2-lyso-GPE and 1-lyso-2-acyl-GPE were utilized to synthesize PE. This is
supported by the observations that ME + H2O2 induced a 28% and 33% decrease in the
cellular levels of 16:0/lyso and 18:0/lyso species, respectively, while the PE level was
increased by 11% relative to the corresponding controls (ME treated cells). When the
levels of LPE become high enough, they are capable of lysing the cell membranes
because of their amphiphilic nature (237, 238). They are, therefore, maintained at very
low levels (239). Their adversary effects involve modulating the activities of various
enzymes (240), increasing the membrane fluidity (241), inhibiting cholinergic signal
transduction (242) and activating cAMP dependent protein kinase A (243). In brain
tissues, lyso-plasmalogens are rapidly used by CoA-independent transacylase enzymes in
the remodeling pathway to re-synthesize plasmalogens (244, 245) in order to maintain
their normal levels in neural membranes (3).
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CHAPTER 5: RESULTS AND DISCUSSION FOR MASS SPECTROMETRY
DATA
5.2 RESULTS
5.1.1 Molecular species composition of ethanolamine phospholipids in N2A cells

Different molecular species of PE-Pls, PE and LPE present in N2A cells were
examined by electrospray ionization tandem quadrupole mass spectrometry (ESIMS/MS) run in the positive ion mode (see methods for details).
A summary of all Etn PL subclasses detected by ESI-MS/MS in N2A cells is
shown in Fig. 15. Molecular species in each subclass and their abundance are shown in
Table 7-9. We identified and quantified a total of 57 molecular species of Etn PL,
comprising 3 species of AAPE (Table 7), 19 species of PE-Pls (Table 7), 23 of PE
(Table 8) and 12 species of LPE (Table 9). As illustrated in Fig. 15, PE-Pls and their
precursors (AAPE) combined account for 54% of the entire Etn PL pool. The cellular
contents of PE and LPE constitute 46% and 1.3% of this pool, respectively. Three
different molecular species of AAPE (34:1-e; 36:1-e and 36:2-e) were identified (Table
7), which constitute 8.1% of the total Etn PL. The most abundant AAPE species is 34:1e contributing 3.2% and 39.6% of total Etn PL and AAPE pool, respectively. This
species (34:1-e) is the precursor for 34:1p PE-Pls species. Interestingly, 34:1p is also the
most prevalent PE-Pls species in the cells, accounting for 10.4% and 23.0% of total Etn
PL and PE-Pls pool, respectively. Both 36:1-e and 36:2-e are also the precursors for PEPls (36:1p and 36:2p PE-Pls species, respectively). They contribute 2.6% and 2.3% to
entire Etn PL pool, respectively. In fact, 36:2p is the second most abundant PE-Pls in
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N2A cells, constituting 11.8% and 2.7% of the entire PE-Pls pool and total ethanolamine
PL, respectively. The first four most prevalent PE-Pls species (34:1p, 36:2p, 36:4p and
38:5p) combined account for 57% and 26% of PE-Pls pool and total Etn PL, respectively.
Table 8 shows the molecular species of PE synthesized by N2A cells. The first
three most predominant species of PE are 34:1, 36:2 and 36:1, making 40.6% of the
entire PE pool and about 18.1% of the total Etn pool.
As shown in Table 9, the contribution of LPE species to the entire pool of Etn PL
in N2A cells is relatively minimal. LPE species only make 1.3% of all Etn PL contents in
the cells. The sn-2 lyso products
produced by the cells included
16:0/lyso,

18:0/lyso

and

1.3 %
LPE
45.8 %
PE-Pls

44.9 %
PE

18:0p/lyso (Table 7). These are

8.0 %
AAPE

generated by phospholipase A2
(PLA2) enzymes that cleave the

Figure 15. Ethanolamine phospholipid profiles in

fatty acyl chains attached to sn-2

N2A cells. See abbreviations on pages Xiii – Xvi.

position of glycerophospholipids. Both 16:0/lyso and 18:0/lyso are generated from PE
species, whereas 18:0p is synthesized from PE-Pls by plasmalogen-selective PLA2 (2).
N2A cells also synthesize sn-1 lyso products. These can be produced by the
phospholipase A1 enzymes (PLA1) (99) or the oxidation by the reactive oxygen species
(15, 16). Nine out of twelve different LPE species synthesized by the cells are sn-1 lyso
products (Table 7). These account for 91% of the entire LPE pool. Both 16:0/lyso and
18:0/lyso combined contribute 8% to the entire LPE pool while the contribution of
18:0p/lyso to this pool is only 2%. The most predominant LPE species in N2A cells are
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lyso/18:0 and lyso/16:0, which account for 40.5% and 16.1% of the LPE pool,
respectively.
Table 7. Molecular species of AAPE and PE-Pls in N2A cells (Mean ± SE)
nmol/mg

% Etn

Assignment

protein

Lipids

34:1-e

1.11 ± 0.12

3.20 ± 0.48

36:1-e

0.92 ± 0.12

2.58 ± 0.37

36:2-e

0.80 ± 0.09

2.25 ± 0.26

32:0p

0.02 ± 0.002

0.05 ± 0.01

32:1p
34:1p

0.36 ± 0.04
3.77 ± 0.47

0.98 ± 0.09
10.43 ± 0.96

36:1p
38:1p
34:2p
36:2p
36:3p
38:3p

0.99 ± 0.16
0.11 ± 0.2
1.09 ± 0.14
1.96 ± 0.26
0.35 ± 0.05
0.43 ± 0.07

2.69 ± 0.31
0.30 ± 0.04
2.98 ± 0.23
5.36 ± 0.36
0.94 ± 0.07
1.17 ± 0.10

40:3p

0.03 ± 0.004

0.07 ± 0.01

36:4p
38:4p
40:4p

1.95 ± 0.25
1.43 ± 0.21
0.14 ± 0.02

5.39 ± 0.56
3.87 ± 0.41
0.39 ± 0.06

36:5p
38:5p

0.17 ± 0.02
1.68 ± 0.22

0.46 ± 0.05
4.59 ± 0.40

40:5p

0.27 ± 0.04

0.74 ± 0.07

38:6p

1.00 ± 0.15

2.73 ± 0.31

40:6p

0.56 ± 0.09

1.52 ± 0.21

40:7p

0.41 ± 0.6

1.10 ± 0.09

e. ether linked (AAPE); p. plasmalogens.
See abbreviations on pages Xiii – Xvi.

76

Table 8. Molecular species of PE in N2A cells (Mean ± SE)
nmol/mg
Assignment
protein
28:0
0.007 ± 0.006

% Etn
Lipids
0.016 ± 0.11

34:0

0.31 ± 0.06

0.79 ± 0.08

36:0

0.28 ± 0.05

0.72 ± 0.08

34:1

2.56 ± 0.45

6.72 ± 0.71

36:1

1.95 ± 0.36

5.03 ± 0.47

34:2

1.38 ± 0.22

3.69 ± 0.43

36:2

2.42 ± 0.41

6.38 ± 0.69

38:2

0.76 ± 0.14

2.00 ± 0.25

34:3

0.08 ± 0.01

0.22 ± 0.03

36:3

0.59 ± 0.10

1.55 ± 0.17

38:3

0.87 ± 0.16

2.26 ± 0.24

40:3

0.13 ± 0.03

0.34 ± 0.05

36:4

0.20 ± 0.04

0.52 ± 0.08

38:4

1.64 ± 0.31

4.27 ± 0.51

40:4

0.24 ± 0.05

0.61 ± 0.06

36:5

0.11 ± 0.02

0.30 ± 0.04

38:5

1.22 ± 0.0.22

3.19 ± 0.37

40:5

0.70 ± 0.13

1.82 ± 0.18

38:6

0.11 ± 0.02

0.29 ± 0.04

40:6

1.07 ± 0.21

2.79 ± 0.33

38:7

0.04 ± 0.01

0.11 ± 0.01

40:7

0.43 ± 0.08

1.13 ± 0.14

40:8

0.06 ± 0.01

0.15 ± 0.02

See abbreviations on pages Xiii – Xvi.
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Table 9. Molecular species of LPE in N2A cells (Mean ± SE)
nmol/mg

% Etn

protein

Lipids

0.015 ± 0.008

0.045 ± 0.028

0.026 ± 0.013

0.081 ± 0.049

18:0p/lyso

0.011 ± 0.007

0.035 ± 0.024

lyso/14:0

0.004 ± 0.002

0.014 ± 0.009

0.072 ± 0.019

0.187 ± 0.039

0.180 ± 0.043

0.468 ± 0.086

lyso/20:3

0.035 ± 0.017

0.088 ± 0.037

lyso/20:4

0.045 ± 0.027

0.103 ± 0.051

lyso/22:4

0.052 ± 0.017

0.121 ± 0.035

lyso/20:5

0.028 ± 0.019

0.069 ± 0.042

lyso/22:5

0.030 ± 0.014

0.078 ± 0.030

lyso/22:6

0.016 ± 0.007

0.040 ± 0.016

Assignment
16:0/lyso
18:0/lyso

lyso/16:0
lyso/18:0

*
*

*
*

* Peaks for these species were differentiated based
on their elution times (see methods for details);
p. plasmalogen. See abbreviations on pages Xiii – Xvi.
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5.1.2 Myo-inositol plus ethanolamine preferentially elevates the levels of
ethanolamine plasmalogen species containing saturated and monounsaturated fatty
acyl chains in N2A cells

We determined the effect of ME treatment on the Etn PL pool. As shown in Fig.
16A, ME treatment increased Etn PL content by 47% relative to control cells (p  0.05).
This treatment induced an overall 73% increase in the AAPE pool, a 62% increase in PE
species, a 26% increase in PE-Pls, and a 125% increase in LPE species (p ≤ 0.05) (Fig.
16B; Table 10).
16A
Etn PL

60

16B
56
a

nmol/mg protein

nmol/mg protein

75

45
30
15

0
H2O2
H
2 O2

Control
Control

ME
ME

48
40

LPE

32

PE

24

AAPE

16

PE-Pls

8

0

ME+
H 2 O2
ME+H2O2

Control

ME

Figure 16. Effects of ME and H2O2 treatments on (A) Etn PL pool; (B) Etn PL subclasses in
N2A cells (Mean ± SE). a. denotes significant differences (p < 0.05; n = 7-8) from control
group. See abbreviations on pages Xiii – Xvi.

For visualization on how each treatment affected the molecular species of Etn PL, we
constructed a heatmap using the Logarithm-base 2 transformed concentration values for
each species measured (Fig. 17A). In this heatmap, the species with an abundance that is
less than 1 nmol/mg protein are shown in blue, whereas those with an abundance that is
above 1 nmol/mg protein are shown in red. The cellular concentration of those that are
shown in white color is equal to 1 nmol/mg protein. Comparing ME treatment versus the
control group shows an effect on some of the Etn PL species. However, the figure does
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not display the magnitude of the changes relative to the control. To have a clear insight
on the magnitude of changes induced by treatments, we calculated the fractional change
(FC) induced by each treatment relative to the standard deviation of the corresponding
control group as shown in Equation (1) and constructed another heatmap figure using
these values (Fig. 17B).

FC =

Treated−Control
SDEV for control

(1)

As illustrated in Fig. 17B, ME increased the levels of all the AAPE species in the
cells. Changes in their cellular levels ranged from 1.5-fold to 2-fold increase and 34:1-e
was the most affected AAPE species by the treatment (p = 0.0004, Table 11). Exposing
cells to ME preferentially enhanced the levels of all PE-Pls species rich in SFA (32:0p)
and MUFA (32:1p; 34:1p; 36:1p and 38:1p) relative to PUFA species (p  0.05; Fig.
17B; Table 11). The
increase ranged from

Table 10 . Effects of ME and H2O2 on PE and PE-Pls
levels (% change relative to control) in N2A cells

26% to 220%. The most

Etn
Subclass

affected PE-Pls species
were 32:0p and 32:1p
(2-fold

increase).

ME

H2O2

ME + H2O2

AAPE

+ 72.7

-7.1

+ 9.9

PE

+ 61.5

+ 0.1

+ 10.8

PE-Pls

+ 25.8

- 27.2

+ 14.7

LPE

+1 25.4

+67.6

-12.2

Figures 18B and 18C
See abbreviations on page

show the effect of treatments on the abundance (nmol/mg protein) of PE-Pls species
containing SFA + MUFA and those containing PUFA, respectively. ME increased the
levels of PE-Pls species containing SFA + MUFA by 60% relative to those measured in
control group (Fig. 18B) and their relative proportion of the pool size increased from
32% to 40% (Fig. 18A). Interestingly, the cellular levels of PE-Pls species that contain
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PUFA were only increased by 10% relative to those measured in the control cells (Fig.
18C, p  0.05), and their relative proportion of the pool size decreased from 68% to 60%
(Fig. 18A). Most of these species showed little or no change in their levels following ME
treatment, except 36:2p species which increased by 49% (p = 0.006). It is worthy to note
that the precursor for this species (36:2-e) was also among the species that were
significantly increased by ME (p = 0.01). Nevertheless, four species in this category
slightly decreased by less than 10% (Table 11), while those for 38:3p and 40:3p
decreased by 10.7% and 18.5%, respectively, although the decrease was not significant.

Figure 17 A. Heatmap showing effects of ME and H2O2 treatments on the
abundance of different molecular species of Etn PLs in N2A cells. The heatmap was
generated using the log-base 2 transform of the concentration values (nmol/mg
protein) for each species. See abbreviations on pages Xiii – Xvi.
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Figure 17 B. Heatmap showing changes induced by ME and H2O2 treatments on different
molecular species of Etn PLs in N2A cells. The heatmap was generated using the log-base
2 transform of the changes in concentration for each species in a treated group relative to
its corresponding control. These changes were calculated using equation (1). See
abbreviations on pages Xiii – Xvi.
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Table 11. Effects of ME and H2O2 treatments on molecular species of
AAPE and PE-Pls in N2A cells (Mean ± SE)

Assignment

Control

34:1-e

1.11 ± 0.12

36:1-e
36:2-e
32:0p
32:1p
34:1p

0.92 ± 0.12
0.80 ± 0.09

nmol/mg protein
H2O2
ME
1.11 ± 0.29
0.83 ± 0.22
0.68 ± 0.18

ME + H2O2

2.17 ± 0.19
1.54 ± 0.15
1.16 ± 0.11

a
a

a

0.02 ± 0.002 0.01 ± 0.003 0.04 ± 0.003
0.36 ± 0.04 0.27 ± 0.07
3.77 ± 0.47

2.84 ± 0.72

0.74 ± 0.06
5.92 ± 0.35

a

a
a
a

2.40 ± 0.50
1.72 ± 0.37
1.25 ± 0.25
0.04 ± 0.01
0.76 ± 0.19
6.16 ± 1.41

36:1p
38:1p
34:2p

0.99 ± 0.16
0.11 ± 0.2
1.09 ± 0.14

0.77 ± 0.20
0.07 ± 0.02
0.78 ± 0.22

1.53 ± 0.15
0.14 ± 0.02
1.33 ± 0.10

36:2p
36:3p
38:3p
40:3p

1.96 ± 0.26
0.35 ± 0.05
0.43 ± 0.07
0.03 ± 0.004

1.39 ± 0.36
0.23 ± 0.06
0.28 ± 0.08
0.02 ± 0.004

2.93 ± 0.19
0.45 ± 0.04
0.39 ± 0.02
0.02 ± 0.002

3.05 ± 0.77
0.50 ± 0.13
0.41 ± 0.10
0.02 ± 0.01

36:4p
38:4p
40:4p

1.95 ± 0.25
1.43 ± 0.21
0.14 ± 0.02

1.41 ± 0.40
1.06 ± 0.30
0.11 ± 0.03

1.80 ± 0.12
1.37 ± 0.08
0.14 ± 0.01

2.41 ± 0.65
1.76 ± 0.46
0.17 ± 0.05

36:5p
38:5p

0.17 ± 0.02
1.68 ± 0.22

0.12 ± 0.03
1.14 ± 0.33

0.16 ± 0.01
1.62 ± 0.12

0.21 ± 0.06
2.13 ± 0.60

40:5p

0.27 ± 0.04

0.19 ± 0.05

0.27 ± 0.01

0.34 ± 0.09

38:6p

1.00 ± 0.15

0.76 ± 0.22

1.11 ± 0.08

1.48 ± 0.41

40:6p

0.56 ± 0.09

0.44 ± 0.12

0.61 ± 0.04

0.80 ± 0.21

40:7p

0.41 ± 0.6

0.27 ± 0.07

0.44 ± 0.05

0.60 ± 018

a

1.62 ± 0.37
0.12 ± 0.03
1.52 ± 0.38

e. ether linked (AAPE); p. plasmalogen; a. differs from control group (p  0.05).
See abbreviations on pages Xiii – Xvi.
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Figure 18. Effects of ME and H2O2 treatments on the (A) proportion of SFA + MUFA-rich
PE-Pls and PUFA-rich PE-Pls relative to PE-Pls pool; (B) abundance of SFA + MUFA-rich
PE-Pls; (C) abundance of PUFA-rich PE-Pls in N2A cells. a. denotes significant differences
(p < 0.05; n = 7-8) from control group. See abbreviations on pages Xiii – Xvi.
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5.1.3

Myo-inositol

plus

ethanolamine

enhances

the

levels

of

phosphatidylethanolamine in N2A cells

ME preferentially increased the PE pool relative to that for PE-Pls (Fig. 16B).
This treatment elevated the PE contents of the cells by 62% relative to the control cells (p
= 0.01). As illustrated in Fig. 17B and Table 12, ME increased significantly the cellular
levels of all PE species (p  0.05), except those for 28:0, 34:3, 40:3, 36:5, 38:5 and 40:8
species. In fact, the increase in the level of 40:3 was nearly significant (p = 0.08).
However, 28:0 was the only PE species that displayed a decrease (30%) in its cellular
level associated with ME treatment, although the decrease was not significant. The
increase in PE levels ranged from 20% (for 34:3 species) to 200% (for 34:0 species).
Interestingly, ME preferentially elevated the levels of PE species that contain SFA and
MUFA (Fig. 19A-B; Table 12), except for 28:0 (Fig. 17B). Their contribution to the PE
pool changed from 30% (control) to 34% (ME group) (Fig. 19A). The abundance
(nmol/mg protein) of PE species containing SFA + MUFA displayed an overall level
increase of 87% relative to those measured in the control group (p < 0.003) (Fig. 19B).
The abundance of PE species that contain PUFA increased by 51% relative to those
measured in the control cells (Fig. 19C, p  0.05).
We also investigated the effect of ME treatment on the concentration of LPE
species in N2A cells. ME treatment elevated the cellular levels of LPE by an average of
2.3-fold relative to control. ME also preferentially elevated the LPE species that contain
SFA (Table 13). The most predominant LPE species were lyso/18:0 and lyso/16:0, which
constituted 46.2% and 20.6% of LPE pool, respectively. ME elevated their cellular
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contents by 2.5-fold and 2.8-fold, respectively. Lyso/18:0 and lyso/16:0 are also the most
predominant LPE species in the control group (Table 13).
5.1.4 Myo-inositol plus ethanolamine blocks the H2O2-induced degradation of
ethanolamine plasmalogens in N2A cells
We determined the impact of H2O2 treatment on the levels of PE-Pls and PE
species in N2A cells. As shown in Fig. 16A, exposing N2A cells to H2O2 decreased their
Etn PL contents by 12% relative to control cells, but the decrease was not significant.
H2O2 induced an overall 7% decrease in the cellular levels of AAPE pool, although the
decrease was not significant. The levels of all PE-Pls species dropped without exception
(Fig. 17B). The decrease in AAPE levels ranged from 20% (for 40:6p) to 42% (for
40:3p). It appeared that all the PE-Pls were prone to degradation regardless of the degree
of saturation and length of the fatty acyl chains. H2O2 induced a 7% decrease in AAPE
pool, a 27% decrease in PE-Pls pool, a 0.1% increase in PE pool and a 68% increase in
LPE pool (Table 10). The cellular levels of PE-Pls species that contain SFA and MUFA
were decreased by 28%, while those that contain PUFA dropped by 25% (Fig. 18A & B).
Interestingly, all the effects associated with H2O2 on the cellular levels of AAPE and PEPls species were blocked when the cells were pre-treated with ME prior to H2O2 exposure
(ME + H2O2 group) (Fig 17B and Table 11). Exceptionally, the levels for 32:0p and
38:1p species decreased by 9 and 13%, respectively, while all other species were either
unaffected or displayed an increase in response to H2O2. In fact, ME + H2O2 group
displayed a 15% average increase in PE-Pls pool relative to that measured in the
corresponding control (ME), although this increase was not significant (Table 10).
Another interesting observation that is worthy to highlight is that ME + H2O2 group
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preferentially increased the PE-Pls that contain PUFA (4-7 double bonds). However,
these species were among those that displayed little or no change following ME treatment
(Fig. 17B, Table 11). These data suggest that pretreating the cells with ME inhibits the
H2O2-induced degradation of PE-Pls in N2A cells.
It was remarkable to observe that H2O2 did not impact the concentration of PE
species in N2A cells (Fig 17B, Table 10, Table 12). In fact, the overall influence of this
treatment on these species was negligible (0.1% increase). Regardless of the degree of
saturation and length of their fatty acyl chains, the PE species are more resilient to H2O2induced degradation (Fig. 19B-C) than the PE-Pls species.

Figure 19. Effects of ME and H2O2 treatments on the (A) proportion of SFA + MUFArich PE and PUFA-rich PE relative to PE pool; (B) abundance of SFA + MUFA-rich PE;
(C) abundance of PUFA-rich PE in N2A cells. a. denotes significant differences (p < 0.05;
n = 7-8) from control group. See abbreviations on pages Xiii – Xvi.
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Table 12. Effects of ME and H2O2 treatments on molecular species of PE in N2A
cells (Mean ± SE)
Assignment
28:0
34:0
36:0
34:1
36:1
34:2
36:2

Control

nmol/mg protein
H2O2
ME

0.007 ± 0.006 0.005 ± 0.003
0.31 ± 0.06
0.28 ± 0.05
2.56 ± 0.45
1.95 ± 0.36
1.38 ± 0.22
2.42 ± 0.41

0.30 ± 0.08

ME + H2O2

0.01 ± 0.002
0.61 ± 0.05

a
a

0.30 ± 0.09

0.52 ± 0.07

2.76 ± 0.77

4.91 ± 0.52

2.07 ± 0.55

3.49 ± 0.27

1.37 ± 0.37

1.93 ± 0.12

2.32 ± 0.59

3.78 ± 0.28

a
a
a
a
a

38:2
34:3

0.76 ± 0.14
0.08 ± 0.01

0.69 ± 0.18
0.08 ± 0.02

1.18 ± 0.12
0.10 ± 0.01

36:3

0.59 ± 0.10

0.53 ± 0.14

0.82 ± 0.08

a
a

38:3
40:3

0.87 ± 0.16
0.13 ± 0.03

0.79 ± 0.20
0.11 ± 0.03

1.35 ± 0.09
0.18 ± 0.02

36:4

0.20 ± 0.04

0.20 ± 0.06

0.31 ± 0.05

38:4

1.64 ± 0.31

1.63 ± 0.45

2.43 ± 0.27

a
a
a

0.01 ± 0.008
0.63 ± 0.13
0.54 ± 0.10
5.07 ± 0.89
3.82 ± 0.82
2.27 ± 0.47
4.24 ± 0.92
1.18 ± 0.22
0.12 ± 0.03
0.95 ± 0.22
1.43 ± 0.30
0.19 ± 0.04
0.35 ± 0.07
2.87 ± 0.65

40:4
36:5

0.24 ± 0.05
0.11 ± 0.02

0.23 ± 0.06
0.11 ± 0.03

0.37 ± 0.03
0.15 ± 0.02

0.43 ± 0.09
0.18 ± 0.04

38:5

1.22 ± 0.0.22

1.11 ± 0.30

1.69 ± 0.19

1.94 ± 0.43

40:5
38:6
40:6
38:7
40:7
40:8

0.70 ± 0.13
0.11 ± 0.02
1.07 ± 0.21
0.04 ± 0.01
0.43 ± 0.08
0.06 ± 0.01

0.76 ± 0.21

1.13 ± 0.12

0.11 ± 0.03

0.19 ± 0.03

1.18 ± 0.33
0.04 ± 0.01

1.78 ± 0.22
0.07 ± 0.01

a
a
a
a
a

0.42 ± 0.11
0.06 ± 0.02

0.66 ± 0.08
0.09 ± 0.01

1.32 ± 0.27
0.21 ± 0.05
2.09 ± 0.42
0.07 ± 0.02
0.74 ± 0.16
0.10 ± 0.02

a. differs from control group (p  0.05). See abbreviations on pages Xiii – Xvi.

88

Table 13. Effects of ME and H2O2 treatments on molecular species of LPE in N2A
cells (Mean ± SE)
% Total ethanolamine phospholipids
Assignment
16:0/lyso

*

Control

H2O2

ME + H2O2

ME

0.015 ± 0.008 0.017 ± 0.007 0.029 ± 0.010

0.021 ± 0.006

0.026 ± 0.013 0.037 ± 0.016 0.055 ± 0.024

0.037 ± 0.012

18:0p/lyso

0.011 ± 0.007 0.022 ± 0.009 0.018 ± 0.010

0.015 ± 0.007

lyso/14:0

0.004 ± 0.002 0.004 ± 0.001 0.006 ± 0.002

0.005 ± 0.001

18:0/lyso

lyso/16:0
lyso/18:0

*

*
*

0.072 ± 0.019 0.051 ± 0.016 0.205 ± 0.054
0.180 ± 0.043 0.121 ± 0.037 0.459 ± 0.102

a
a

0.196 ± 0.061
0.434 ± 0.119

lyso/20:3

0.035 ± 0.017 0.131 ± 0.062 0.071 ± 0.046

0.055 ± 0.029

lyso/20:4

0.045 ± 0.027 0.211 ± 0.099 0.106 ± 0.063

0.091 ± 0.044

lyso/22:4

0.052 ± 0.017 0.019 ± 0.004 0.061 ± 0.027

0.043 ± 0.015

lyso/20:5

0.028 ± 0.019 0.054 ± 0.031 0.026 ± 0.017

0.013 ± 0.006

lyso/22:5

0.030 ± 0.014 0.131 ± 0.061 0.068 ± 0.042

0.058 ± 0.029

lyso/22:6

0.016 ± 0.007 0.067 ± 0.031 0.039 ± 0.024

0.032 ± 0.016

* Peaks for these species were differentiated based on their elution times (see methods for
details); p. plasmalogen; a. differs from control group (p  0.05). See abbreviations on pages Xiii
– Xvi.
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5.1.5 Myo-inositol plus ethanolamine blocks the H2O2-induced increase in
lysoglycerophosphoethanolamine levels in N2A cells

The effect of H2O2 on the concentration of LPE species in N2A cells was also
assessed. As shown in Fig. 20A-C, H2O2 changed the balance between the levels of LPE
that contain PUFA and those that contain SFA. This treatment induced a 19% decrease in
the levels of LPE containing SFA relative to those in the control group, although this
decrease was not significant (Fig. 20B). Conversely, the levels of LPE containing PUFA
displayed a 3-fold increase relative to those in the control group (p  0.05) (Fig. 20C). In
this category, the species that were preferentially affected include lyso/20:4, lyso/22:5,
lyso/22:6 and lyso/20:3, which increased by 4.7-fold, 4.4-fold, 4.2-fold and 3.7-fold,
respectively (Table 13). Lyso/22:4 is the only PUFA LPE species that decreased in
concentration following H2O2 treatment. Interestingly, in response to H2O2 the levels of
all the sn-1 lyso products that contain SFA decreased (lyso/14:0, lyso/16:0 and
lyso/18:0), while those for sn-2 lyso products (18:0p/lyso, 16:0/lyso and 18:0/lyso) were
slightly increased (Fig. 17B, Table 13). In fact, exposing cells to H2O2 increased the
level of 18:0p/lyso product by 2-fold relative to that measured in the control group. Our
data show that only PE-Pls species dropped in their levels by 27% following exposure to
H2O2, whereas those for PE species remained unchanged (Fig. 20D), suggesting that
most of the LPE were generated from the degradation of PE-Pls. Table 14 identifies the
probable parents (PE-Pls) for LPE species in H2O2 group and ME + H2O2 group based on
the reports showing that sn-1 position of PE-Pls contains C16:0, C18:0, C18:1 acyl
chains (48-50). Microsoft Excel software was used to perform the correlation analyses
between LPE species and their probable PE-Pls parents (using concentrations values).
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The Table 14 only highlights correlations where r2 was  0.5. The unique species of
lysoplasmalogen (18:0p/lyso) strongly correlated with nine out of twelve probable PE-Pls
parents in H2O2 group, while in ME + H2O2 group this species only correlated with five
PE-Pls species. These data suggest that plasmalogen-selective PLA2 was relatively more
active in H2O2 group than in ME + H2O2 group. For instance, 18:0p/lyso correlated well
with 34:1p in H2O2 group (r2 = -0.9), while displaying no correlation with this same PEPls species in ME + H2O2 group (r2 = -0.3). This may not be surprising since H2O2
induced a 2-fold increase in 18:0p/lyso level (Fig. 23), while the level of this species
decreased by 17% in ME + H2O2 group (Fig. 23). In order to assess how H2O2 treatment
affected the balance between the levels of PE-Pls and those of LPE in the cells, we
calculated the LPE/PE-Pls ratio. As illustrated in Fig. 20E, this ratio increased by 2.3fold relative to that calculated for the control group (p  0.05). Since our data show that
H2O2 preferentially increased the cellular levels of LPE containing PUFA (from 34% to
52%) (Fig. 20A), we then calculated two ratios: (1) the LPE/PE-Pls ratio for PUFAcontaining species (Fig. 20F) and (2) the LPE/PE-Pls ratio for (SFA+MUFA)-containing
species (Fig. 20G). As shown in Fig. 20F, the first ratio increased by 4.5-fold relative to
that calculated for the control group (p  0.05), while the second ratio (Fig. 20G) did not
change, suggesting that H2O2 preferentially induced oxidation of PE-Pls rich in PUFA.
Amazingly, the H2O2-induced degradation of PE-Pls was not observed in the cells
pre-treated with ME prior to H2O2 exposure (ME + H2O2 group) (Fig. 17B, Table 13).
Additionally, no significant changes in the cellular levels of LPE were observed with ME
+ H2O2 treatment when compared to control cells (Fig. 20C, Fig. E-G). It is interesting to
note that this treatment yielded a 13% decrease in LPE pool, while that in H2O2 group
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increased by 39% relative to corresponding control (Fig. 20D). Additionally, while the
levels of PE species were mostly unaffected by H2O2 treatment, those cells pretreated
with ME and then exposed to H2O2 showed an 11% increase in the level of these species
(although not statistically significant), and an even larger increase (15%) in PE-Pls levels
(Fig. 20D). These data suggest that PE species are more resistant to H2O2-mediated
degradation. The data also implies that the levels of PE-Pls species are not affected by
H2O2 only when the cells are pre-treated with ME.
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Figure 20A-C. Effects of ME and H2O2 treatments on the (A) proportion of SFA-rich LPE
and PUFA-rich LPE relative to LPE pool; (B) abundance of LPE containing SFA; (C)
abundance of LPE containing PUFA in N2A cells. a. denotes significant differences (p <
0.05; n = 7-8) from control group. See abbreviations on pages Xiii – Xvi.
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Figure 20D-G. Effects of ME and H2O2 treatments on the (D) LPE levels (shown here as
% change relative to corresponding control in N2A cells. The % change for PE in H 2O2
group is near zero (0.1%), thus only error bar is showing. (E) LPE/PE-Pls ratio; (F)
LPE/PE-Pls ratio for PUFA-containing species; (G) LPE/PE-Pls for (SFA + MUFA)containing species; a. denotes significant differences (p < 0.05; n = 7-8) from control
group. See abbreviations on pages Xiii – Xvi.
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Table 14. Probable PE-Pls parents of LPE for control cells (C) exposed to H2O2 and ME-

treated cells (T) exposed to H2O2 (T) based on the assumption that the sn-1 position of
PE-Pls contains C16:0, C18:0 and C18:1 acyl chains (48-50). The values highlighted in
yellow indicate the length of acyl chains that PE-Pls must lose in order to yield the
corresponding LPE species. The negative values indicate the correlation coefficients
between LPE species and probable PE-Pls parent. Only correlations where r2 was  0.5
are shown in the table. L: lyso; C: control; T: treated.
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5.2 DISCUSSION
5.2.1 Composition of Ethanolamine phospholipids in N2A cells
We have demonstrated that treating N2A cells with ME increases PE-Pls, PE, and
other non-Etn PL pools, and provides protection against H2O2-mediated oxidative stress.
We have also shown that exposing these cells to H2O2 reduces the level of the PE-Pls
pool and increase that of LPE without significantly affecting PE levels. The main
emphasis of this section of the study was to determine (1) which Etn PL molecular
species are synthesized by N2A cells and (2) how they are affected by ME treatment and
H2O2–induced oxidation. In regard to molecular species composition within Etn PL
subclasses, PE-Pls and their precursor species (AAPE) combined contribute 54% to the
entire pool of Etn PLs. This contribution is similar to what Han et al. (246) have reported
in neurons. Han et al., (246) have indicated that PE-Pls constitute about 60 mol% of Etn
PL pool in neurons and synaptosomes, while in non-neuronal brain cell membranes, their
contribution can even exceed 80%. We found that 34:1p is the most abundant PE-Pls
species in the cells, representing 23% of the entire PE-Pls pool. Interestingly, 34:1-e is
also the most predominant AAPE species (40% of the AAPE pool), which is an
immediate precursor for 34:1p PE-Pls species. We also found that 34:1 is the most
predominant PE species constituting 15% of the PE pool. Each of these three species has
34 carbons and one double bond in their acyl chains. The only distinguishing feature is
the type of bonds attaching their acyl chains at the sn-1 position to the glycerol backbone.
It has been reported that the acyl chain at the sn-1 position is typically C16:0, C18:0 or
C18:1 (3, 5, 39-41). Additionally, substrate specificity studies which investigated the
selectivity of alkylglycerophosphate acyltransferase (LPAAT) also known as alkyl/acyl96

glycero-3-phosphate acyltransferase (AAG3P-AT; EC 2.3.1.51) on different acyl-coA
species (16:0, 18:0, 18:2, 20:4, 22:4, 22:6) have shown that LPAAT specificity for acyl
chains depends on the concentration of 1-alkyl-sn-glycero-3-phosphate (its substrate)
(79). This enzyme prefers using polyunsaturated acyl-CoA over saturated species when
1-alkyl-sn-glycero-3-phosphate is available at low concentrations (79). If these conditions
are also applied to N2A cells, the concentration of 1-alkyl-sn-glycero-3-phosphate is
probably at a high level to the point where LPAAT actively esterifies C16:0 and C18:0
acyl chains at the sn-2 position of 34:1-e and 36:1-e AAPE species. Therefore, the 34:1-e
and 36:1-e AAPE species would correspond to 18:1-e/16:0 and 18:1-e/18:0, giving rise
to 34:1p and 36:1p PE-Pls species (corresponding to 18:1p/16:0 and 18:1p/18:0 species).
Fleming and Hajra (79) carried out investigations on the specificity of this enzyme in
kidney, spleen, heart, lung, liver and brain rat tissues and concluded that the activity of
acyltransferase enzyme could partially determine the composition of fatty acyl groups
esterified in lipids. We cannot conclude for sure that the acyltransferase in N2A cells is
also behaving in the similar manner to this enzyme in rat tissues. Horrocks and Sharma
(247) reported that the sn-2 position of PE-Pls in gray matter is rich in 20:4, 22:4 and
22:6 acyl chains, whereas in white matter, 18:1, 20:1 and 22:4 are the most abundant acyl
chains attached at this position. This is another example of variations in composition of
acyl chains in phospholipids which again depend on the tissue types and the acyl chain
specificity for the enzymes involved in acylating the phospholipids.
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5.2.2 Myo-inositol plus ethanolamine preferentially increases ethanolamine
plasmalogens containing saturated and monounsaturated fatty acids in N2A cells
To our best knowledge, this is the first study to reveal that SFA + MUFA-rich PEPls and PE species in N2A cells are more sensitive to ME treatment than PUFA-rich
species. Exposing the cells to ME increased the cellular levels of PE-Pls and PE pools
containing SFA and MUFA. Although the mechanism behind these changes remains to
be elucidated, it has been shown that myo-inositol can be metabolized into DHAP via the
pentose pathway (188). DHAP is also the first building block for PE-Pls biosynthesis
(Fig. 4). Although it is unclear why N2A cells respond to ME treatment by preferentially
elevating the levels of SFA + MUFA-rich PE-Pls and PE species, we can speculate that
this treatment is probably inducing an increase in the cellular level of 1-alkyl-2-acyl-snglycero-3-phosphate, a substrate for AAG3P-AT in PE-Pls biosynthesis pathway. This
enzyme esterifies an acyl chain at the sn-2 position of 1-alkyl-sn-glycero-3-phosphate to
form 1-alkyl-2-acyl-sn-glycero-3-phosphate. It has been shown that this enzyme prefers
using SFA species when the concentration of 1-alkyl-sn-glycero-3-phosphate is at the
high level (79). We cannot rule out that ME treatment increases the pool size of 1-alkylsn-glycero-3-phosphate, thus forcing the enzyme to preferentially use SFA over PUFA
species. Changes in the composition of fatty acids constituents of the Etn PL in the cell
membranes potentially have an impact on the cellular biological processes. In the central
nervous system, the primary role for plasmalogens is to serve as structural constituents of
the cell membranes (246). They are involved in different biophysical functions such as
bilayer thickness, membrane fusion, membrane phase (51, 55), and reservoirs for second
messengers (149, 248). The hydrophobicity of the plasmalogen’s head group can be
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affected by the lack of a carbonyl group at the sn-1 position and the structural orientation
of the acyl chain attached at the sn-2 position (249). This conformation promotes a strong
intermolecular hydrogen bonding between the head groups and allows the plasmalogen
species to adopt an inverse hexagonal phase. This has a profound implication on the cell
membrane processes such as lipid packing, fluidity, and how these species interact with
other molecules anchored in the neural membranes such as ion channels and receptors
(249). There are reports that describe the role of plasmalogens in shaping the cell
membrane. In fact, cell membranes rich in plasmalogens with a high percentage of
MUFA at the sn-2 position such as myelin are more compact and stable (42, 241).
Conversely, those that are highly rich in unsaturated acyl chain at the sn-2 position,
mostly in gray matter, are thought to be involved in facilitating membrane fusion (250,
251), intercellular communication and serve as storage for bioactive signaling lipid
molecules (246, 249, 252). This indicates the importance of the degree of saturation in
the fatty acyl chains attached to plasmalogens as it relates to cell membrane function.
Plasmalogens are known to have a tendency of packing more closely with one another,
thus reducing the membrane fluidity and passive ion permeability (43). Moreover, SFA
pack more tightly than PUFA species. It is possible that ME treatment enhances these
properties, thus decreasing the membrane fluidity, which may affect access of ROS to
membrane lipids.
5.2.3 Myo-inositol plus ethanolamine protects against the H2O2-induced degradation
of ethanolamine plasmalogens in N2A cells
Our data indicate that H2O2 induced a 27% loss in PE-Pls pool and 39% increase
in LPE levels in N2A cells. These were the same cells that displayed 56% survival rate
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when they were exposed to H2O2. Strikingly, this loss was not observed when the cells
were pre-treated with ME prior to H2O2 exposure (ME + H2O2 group). Additionally, ME
+ H2O2 was the same treatment that elevated the cell survival to 79.5%. There seems to
be a link between H2O2-induced decrease in the cellular levels of PE-Pls species and an
increase in their degradation by-products (LPE). Most importantly, only PE-Pls species
appeared to be affected by this treatment as the levels of PE remained unchanged in the
cells. PE-Pls and PE have similarities in the chemical structure. The only distinguishing
feature is the types of linkage that attaches the acyl chain at their sn-1 position to the
glycerol backbone. The acyl chain in PE-Pls is attached through a vinyl ether bond while
that for PE is esterified to the backbone via an ester linkage. Between these two linkages,
investigators have demonstrated that the vinyl ether bond is the most sensitive to
oxidation (3, 5, 39-41). We have also shown that this bond is indeed the most vulnerable
to hydrochloric acid hydrolysis (Fig. 21A-B). Figure 21A shows a
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P NMR spectrum

generated using the lipid extract, while Figure 21B shows a spectrum generated using the
same lipid extract but exposed to hydrochloric acid (12 M) fumes for 1 h. As the Figure
21B shows, none of the peaks for other phospholipids were affected by HCl, including
that for PC-Pls, except the peak for PE-Pls. Hydrolysis of this PL gave rise to LPE peak
in the spectrum which was not apparent before subjecting this extract to HCl fumes. We
also used these two samples to run MS/MS analyses for Etn PL species (data not shown).
We observed that all the LPE species generated by HCl hydrolysis were lacking the acyl
chain at sn-1 position (data not shown). The peak for PE species was not affected by HCl
treatment, suggesting that these LPE species were formed from PE-Pls hydrolysis. These
observations highlight the sensitivity of the vinyl ether bond at the sn-1 position of PE-
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Pls to HCl hydrolysis as compared to ester linkage at the sn-2 position. This constitutes
another piece of evidences that this bond is more vulnerable to hydrolysis as compared to
an ester or ether bond. Similar observations on the vinyl ether bond’s susceptibility to
HCl hydrolysis have been reported (178). All these observations strongly support the
hypothesis that an increase

21B

in LPE levels in the cells
primarily resulted from the

PE

LPE
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P NMR spectra showing the phospholipid

profiles of lipid extract (A) before and (B) after being
exposed to HCl (12 M) fume for 1 h. See abbreviations on
pages Xiii – Xvi.

homeostasis requires a balance between phospholipid biosynthesis, degradation and
remodeling (52), which also requires a considerable amount of ATP (89). Both a loss of
PE-Pls and an increase in LPE in the cell membranes will surely inflict a significant
impact on the integrity of the cell membranes and their functions. It is not clear if a
decrease in the PE-Pls levels following an H2O2-induced oxidative stress in N2A cells
resulted from an increase in (a) oxidation of these species (b) the activity of
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phospholipase A1, which enzymatically cleaves the acyl chains of PL at the sn-1 position
(99) or (c) a combination of both. Regardless of the trigger for PE-Pls degradation, this
effect was blocked by pre-treating the cells with ME prior to H2O2 treatment.

Figure 22. A schematic diagram showing the degradation and re-acylation pathways of
ethanolamine phospholipids. See abbreviations on pages Xiii – Xvi.

The cells control the levels of LPE by two different mechanisms as shown in Fig.
22. First, cells can re-acylate the LPE, thus forming a new PE-Pls or PE species. This
process is carried out by acyltransferase enzymes (51). The second option involves
further hydrolyzing the LPE by lysophospholipases to generate free fatty acids and
glycerophospho-bases (96, 99-101). Our data show that H2O2 uniformly induced a
degradation of PE-Pls regardless the levels of saturation of their acyl chains (Fig. 17B).
However, we were surprised to observe that the LPE/PE-Pls ratio for SFA + MUFA
species remained unchanged (Fig. 20F), but the LPE/PE-Pls ratio for PUFA species
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increased about 4-fold following H2O2 treatment (Fig. 20E). This indicates that the cells
failed to re-acylate the LPE containing PUFA, and/or inhibited the further degradation of
these species into glycerophosphoethanolamine (GPE). This suggests that H2O2
negatively affected the activities of the enzymes involved in both processes. Moreover,
there was a significant increase in the cellular levels of GPE following H2O2 exposure
(Fig. 14, see results for NMR data). The increase in GPE production likely resulted from
the degradation of LPE species containing SFA since H2O2 treatment yielded a 19%
decrease in the level of these species. It is worthy to note that the LPE/PE-Pls ratio for
PUFA species (Fig. 20E) and SFA + MUFA species (Fig. 20 F), as well as the GPE (Fig.
14B) levels were all normal in the ME + H2O2 group when compared to the
corresponding control (ME). The mechanisms by which LPE and GPE levels were
controlled in ME + H2O2 group and how those in H2O2 group were altered are not known.
We showed that ME treatment preferentially increased the levels of PE-Pls species
containing SFA + MUFA, which presumably strengthens the integrity of cell membrane.
Neural cells are particularly vulnerable to oxidative injury because they contain high
levels of PUFAs (51) and don’t possess sufficient reduced glutathione (139). Our data
show that cells pre-treated with ME prior to H2O2 exposure had more PE-Pls containing
SFA + MUFA to spare under oxidative stress, presumably preserving PE-Pls species that
contain PUFA. The only PE-Pls species that decreased under ME + H2O2 treatment were
32:0p (9% decrease) and 38:1p (13% decrease). It is possible that these species were
preferentially targeted by oxidative damage. If degrading PE-Pls was the mechanism of
ME-induced protection against oxidative stress, we would have observed a significant
increase in LPE and/or GPE. However, this wasn’t the case. A couple of explanations
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could explain these observations. Assuming that PE-Pls were also degraded under this
treatment, (1) the resulting LPE by-products were re-acylated to re-form PE-Pls (from
lysoplasmalogens) and PE (from 1-lyso-2-acyl-GPE) to maintain the normal levels of Etn
PLs. In fact, both LPE species containing PUFA (Fig. 20B) and those containing SFA
(Fig. 20A) decreased by 20% and 8%, respectively, although the decrease was not
significant. This suggests that ME + H2O2 treatment increased the acyltransferase
activities and decreased the activities of hydrolase enzymes. Additionally, 18:0p/lyso
species decreased by 17%, suggesting that the treatment inhibited the activity of
lysoplasmalogenase. All these observations are supported by a decrease in GPE levels
(64%). (2) It is possible that the pool was replenished through the de novo biosynthesis
pathway. This is supported by the observation that the levels of AAPE species increased
by 10% following ME + H2O2 treatment. (3) We cannot rule out that the activities of
PLA1 and PLA2 were increased, but PE-Pls pool was maintained at the normal levels
through the mechanisms laid out under scenarios (1) and (2). The homeostasis of Etn
PLs in ME + H2O2 was maintained at the normal level. This could probably explain why
a high rate of cell survival to H2O2 exposure was observed in ME treated group.
We only measured one species of lysoplasmalogens (18:0p/lyso) in N2A cells.
H2O2 treatment induced a 2-fold increase in the cellular level of this species when
compared to that in the control cells. Strikingly, the level of this species in ME + H 2O2
cells was unchanged relative to corresponding control (ME). It has been reported that
oxidized phospholipids resulting from ROS are capable of inducing changes in the micro
viscosity of the cell membranes due to changes in structural composition of
oxidized/unoxidized species, thus increasing the substrate availability for phospholipase
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A2 (153, 253, 254). In brain tissues, lysoplamalogens are generated by plasmalogenselective phospholipase A2 (3) when it cleaves the acyl chain esterified at the sn-2
position of the plasmalogen’s glycerol backbone. In these tissues lysoplamalogens are
either rapidly used by CoA-independent transacylase enzyme in the remodeling pathway
to re-synthesize plasmalogens (244, 245) in order to maintain their normal levels in
neural membranes (3) or cleaved by lysoplasmalogenase to form GPE. When the levels
of lysoplasmalogens become high enough, they are capable of lysing the cell membranes
because of their amphiphilic nature (237, 238). They are therefore, maintained at very
low levels (239). Their adversary effects include modulating the activities of various
enzymes (240), increasing the membrane fluidity (255), inhibiting the cholinergic signal
transduction (242) and activating the cAMP dependent protein kinase A (243).
Alternative routes for lysoplasmalogen utilization include being enzymatically
hydrolyzed by phospholipase C to form 1-alkenyl-glycerol (256) and phospholipase D
that yield plasmenic acid (alk-1-enyl-glycerophosphatidic acid) (257). Lysoplasmalogens
can also be degraded by lysoplasmalogenase enzyme also known as alkenyl ether
hydrolase

(alkenylglycerophosphoethanolamine

hydrolase,

alkenylglycerophosphocholine hydrolase, and alkenylglycerohydrolase) (233-235). This
enzyme is highly specific for glycerophospholipids containing a vinyl-ether linkage at sn1 and a hydroxyl (lyso) at sn-2, and acts with nearly equal efficiency on ethanolamine
and choline classes (236). It has been proposed the lysoplasmalogenase serves at
maintaining lysoplasmalogens at low levels in order to prevent their toxicity (234, 236).
It has been established that lysoplasmalogenase catalyzes the hydrolysis of the vinyl ether
linkages on the lysoplasmalogens (lysoplasmenylcholine or lysoplasmenylethanolamine)
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to

generate long chain

fatty aldehydes

and

glycerophosphoethanolamine or

glycerophosphocholine moieties depending on the substrate (233-235). They are also
involved in the hydrolysis of the vinyl ether bond on 1-alkenyl-glycerol to form a fatty
aldehyde and glycerol (233, 234, 258). Our data suggest that the H2O2 treatment may
have inhibited the activity of lysoplasmalogenase since the level of lysoplasmalogen
(18:0p/lyso) was elevated (2-fold increase) with this treatment. Conversely, we showed
that ME + H2O2 treatment may have enhanced the activity of this enzyme since the level
of 18:0p/lyso was decreased by 17%. Although the mechanism involved is not known, a
simple speculation would suggest that ME probably blocked the H2O2-mediated effect on
lysoplamalogenase activity.
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CHAPTER 6: SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS
6.1 SUMMARY
The main goal of this study was to (1) assess if myo-inositol +/- ethanolamine
treatments increase ethanolamine plasmalogens in N2A cells and provide protection
against H2O2-induced oxidative stress, and (2) determine the molecular species of
ethanolamine phospholipids (PE-Pls, PE and LPE) that are preferentially affected by
these treatments. These studies included four specific aims. NMR and mass spectrometry
were used to analyze the samples. Table 16 illustrates how the measurements from both
analytical methods compare.
Table 15. Etn PLs measured with NMR and Mass spectrometry (nmol/mg protein)

As shown in Table 15, AAPE were not quantified by NMR. It is possible that their
resonance in 31P NMR spectrum was buried under the tall and broad peaks for PE-Pls and
PE since they share structural similarities and the only feature that distinguish them is the
linkage of their acyl chains at sn-1 position (ether, vinyl ether and ester linkages for
AAPE, PE-Pls and PE, respectively). In general, concentrations for PLs measured with
NMR are slightly higher than those measured with mass spectrometry, but the differences
are not that great (20% average difference).
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Specific aim 1. This aim was designed to assess the phospholipid contents of N2A cells,
with specific interest in PE-Pls. The data show that N2A cells synthesize a variety of
phospholipids including PE-Pls, PE and LPE. Choline phospholipids constitute the most
abundant phospholipid class, accounting for more than 50% of the entire PL pool.
Although the contribution of ethanolamine phospholipids to this pool is about half of that
of choline PL, they are also the second most contributor to this pool. PE-Pls and PE
contribute equally to the Etn PL pool (45.8% and 44.9%, respectively). A small portion
of this pool (1.3%) is made by the degradation by-products (LPE) of PE-Pls and PE. PEPls precursors (AAPE) are also less abundant (8% of total Etn PLs) in N2A cells.
Specific aim 2. This aim was intended to examine the effects of myo-inositol alone (M),
ethanolamine alone (Etn) and myo-inositol plus ethanolamine (ME) treatments on the
level of myo-inositol, phosphoethanolamine (PEtn) and phospholipids in N2A cells, with
a special interest in PE-Pls. As expected, M and ME increased myo-inositol content of the
cells (3-fold increase) relative to that in the controls, while Etn and ME enhanced that of
PEtn (3.6-fold and 8-fold increase, respectively). Etn and M had no significant effect on
the total PLs.

However, ME significantly enhanced the synthesis of PLs (2.4-fold

increase), PE-Pls and PE (3-fold increase) relative to control group. Most of the other
non-Etn PLs were increased by 2-fold, except for LPI which increased by 4-fold. Taken
together, ME significantly enhanced the levels of myo-inositol, PEtn, Etn PLs and other
non-Etn lipids in the cells.
Specific aim 3. This aim was designed to assess the effects of M, Etn and ME treatments
on N2A cell protection against hydrogen peroxide-induced oxidative stress. A dose
response curve for H2O2 indicated that exposing the cells to 650 M H2O2 for 24 h yields
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53% ± 1.7 cell viability. Pre-treating N2A cells with Etn alone for 24 h before exposing
them to H2O2 for an additional 24 h did not provide protection against H2O2-induced
oxidative stress. However, pre-treating these cells with M improved significantly the cell
viability (62% ± 1.2), and pretreatment with ME yielded a robust cell survival to H2O2
exposure (79.5% ± 0.6). ME is the same treatment that displayed a significant 3-fold
increase in PE-Pls and PE and about 2-fold increase in most other non-Etn lipids. It is
also noteworthy that PE-Pls levels in the cells prior to H2O2 treatment highly correlated
(r2 = 0.95) with the cell viability following this treatment, suggesting that increasing the
baseline level of PE-Pls can help the cells cope with oxidative damage. Taken together, it
appears that ME treatment provided protection against H2O2-induced death.
Specific aim 4. The purpose of this aim was to examine the impact of H2O2 on the
molecular species of ethanolamine phospholipids in N2A cells with and without ME
treatment. We were especially interested in the effects on PE-Pls species and their
degradation by-products (LPE and GPE). The molecular species of Etn phospholipids
measured in N2A cells include 3 species of AAPE, 19 species of PE-Pls, 23 of PE and 12
species of LPE. PE-Pls species and their precursors (AAPE) combined account for
approximately 54% of the entire Etn PL pool in N2A cells, while PE and LPE constitute
about 45% and 1% of this pool, respectively. The most abundant AAPE species is 34:1-e
(a precursor for 34:1p PE-Pls species). Interestingly, 34:1p is also the most prevalent PEPls species in the cells. The PE-Pls species that are rich in PUFA account for 68% of the
entire PE-Pls pool. The most predominant species of PE is 34:1 and accounts for 15% of
the entire PE pool. PE species containing PUFA make 70.1% of the PE pool. Nine out of
twelve different LPE species measured in N2A cells are sn-1 lyso products and account
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for 91% of the entire LPE pool. The most predominant LPE species in N2A cells are
lyso/18:0 and lyso/16:0, which account for 40.5% and 16.1% of the LPE pool,
respectively. It is also worthy to highlight that 66% of LPE pool purely consists of the
LPE-SFA rich species.

6.1.1 Myo-inositol plus ethanolamine preferentially increases ethanolamine
plasmalogens containing SFA + MUFA in N2A cells

ME increased the PE-Pls pool by 200% relative to the control. Although the
mechanism by which this treatment enhances the levels of PE-Pls in N2A cells is not
known, it is possible the treatment increases the substrates required in the biosynthesis
pathway of PE-Pls. Here is the supporting evidence. First, ME treatment induced an 8fold increase in PEtn pool (p < 0.0001) relative to the control group. PEtn is a substrate
for ECT1 enzyme that synthesizes CDP-ethanolamine (CDP-Etn) in the Kennedy
pathway (Fig. 4) (86, 87). CDP-Etn combines with 1-alkyl-2-acyl-sn-glycerol to form 1alkyl-2-acyl-GPE (AAPE), a precursor for PE-Pls (Fig. 4). Second, ME mediated a 3-fold
increase in myo-inositol content (p < 0.05) of the cells. It has been shown that myoinositol can be metabolized into DHAP (187, 188), a first substrate required in the
pathway leading to the biosynthesis of 1-alkyl-2-acyl-sn-glycerol and PE-Pls (Fig. 4).
From our data, it is possible that myo-inositol influenced the level of PE-Pls by increasing
the peroxisomal DHAP pool used in the biosynthesis of PE-Pls. Etn alone induced a 3.6fold increase in PEtn levels in the cells (p < 0.05) but failed to enhance the cellular levels
of myo-inositol and PE-Pls. Similarly, myo-inositol alone induced a 3-fold increase in the
cellular level of myo-inositol (p < 0.05), but did not significantly affect the levels of PEtn
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and PE-Pls in the cells. Both, CDP-Etn (metabolite of PEtn) and 1-alkyl-2-acyl-snglycerol (probable metabolite of myo-inositol) molecules are indispensable substrates for
the biosynthesis of PE-Pls (5, 6, 39). Only combining myo-inositol and Etn in one
treatment (ME) upregulated the pathways leading to the synthesis of substrates that are
required for the biosynthesis of PE-Pls. Third, ME increased the cellular levels of AAPE
species (precursors for PE-Pls) by 73%. Other investigators have suggested that the effect
of myo-inositol on PE-Pls levels may be associated with an increase in NADPH pool
since myo-inositol’s metabolism into DHAP generates 2 molecules of NADPH (55).
However, our data do not support this hypothesis since myo-inositol alone failed to
enhance the levels of PE-Pls in N2A cells.
It was interesting to observe that ME treatment changed the proportion of PUFA
versus SFA+MUFA present in plasmalogens. The PUFA:SFA+MUFA-rich PE-Pls
changed from 68/32% (control) to 60/40% (ME). ME treatment preferentially enhanced
the levels of PE-Pls species containing SFA+MUFA. The mechanism involved in this
preferential change in the PE-Pls pool is not known. However, it is known that (1)
predominant fatty acyl chains attached to sn-1 position of plasmalogens in mouse and
human brain are SFA (C16:0 and C18:0) and MUFA (C18:1) accounting for 98- 99% of
the acyl chains at this position (48-50), (2) FAR1 enzyme that provides fatty alcohols
esterified at the sn-1 position prefers these fatty acids as substrates (64), and (3) AAG3PAT enzyme that esterifies acyl chains at the sn-2 position prefers using saturated acylCoA over polyunsaturated species when 1-alkyl-sn-glycero-3-phosphate (a precursor for
AAPE) is available at high concentrations (79). Our data show that ME led to an increase
in AAPE (by 73%), suggesting that this treatment increased the concentrations of 1-alkyl111

sn-glycero-3-phosphate in N2A cells leading to increased cellular levels of PE-Pls
species rich in SFA + MUFA over species containing PUFA.
6.1.2 Myo-inositol plus ethanolamine inhibits H2O2–induced increase in degradation
of ethanolamine plasmalogens and their degradation by-products, and increases
N2A cell viability against oxidative stress

Exposing N2A cells to H2O2 yielded a poor cell survival (56%) and an overall
decrease in PE-Pls level by 27%. This treatment did not significantly affect the
proportion of PUFA-rich PE-Pls and SFA+MUFA-rich PE-Pls (68/32% for control vs.
67/33% for H2O2, Fig. 18A), suggesting that these PE-Pls pools were uniformly affected
by the treatment (28 mole % and 25 mole % decrease, respectively). H2O2 treatment did
not have an effect on PE pool in the cells. However, a completely different response to
H2O2 was observed when the cells were pre-treated with ME prior to H2O2 exposure (Fig.
23). First, pre-treating cells with ME provided protection against H2O2-induced cell death
(80% cell survival). Second, instead of losing PE-Pls as seen with H2O2 treatment, ME +
H2O2 induced (1) an overall 15% increase in PE-Pls pool relative to corresponding
control (ME), (2) a 22% increase in the pool of PE-Pls species containing PUFA, (3) and
a 4% increase in PE-Pls species rich in SFA+MUFA. It is worthy to note that prior to
exposing ME treated cells to H2O2, the pool of PE-Pls containing SFA+MUFA was
greater than that containing PUFA (SFA+MUFA > PUFA). But after H2O2 treatment, the
abundance of these pools of PE-Pls flipped (PUFA > SFA+MUFA). The possible
explanations could be that (1) H2O2 exposure induces an increase in synthesis of PUFArich PE-Pls species, (2) the elevated levels of SFA+MUFA pool are preferentially sacrificed,

112

and/or (3) the turnover rate for PUFA species is increased. Cells treated with ME + H2O2

increased their PE content by 11% relative to their corresponding controls (ME treated
cells), suggesting that biosynthesis of PE was increased or the turnover rate was influenced by
exposure to H2O2.

A decrease in PE-Pls levels for the cells treated with H2O2 was associated with an
overall 39% increase in LPE content. Nine out of twelve LPE species measured lack acyl
chains at sn-1 position of their glycerol backbones, suggesting an increase in vinyl ether
bond oxidation, PLA1 activity or both. The observation that H2O2 treatment did not affect
the cellular level of PE suggests that LPE species were mostly generated from the
degradation of PE-Pls species. The proportion of PUFA-rich LPE:SFA-rich LPE changed
from 34/66% (control group) to 52/48% (H2O2 group) (Fig. 20A), suggesting an H2O2induced preferential degradation of PUFA-rich PE-Pls species. However, data on PE-Pls
indicate a uniform degradation of both PE-Pls pools. Given that (1) LPE pool containing
PUFA increased by 3-fold, (2) LPE rich in SFA decreased by 19%, (3) lyso-PE-Pls
(18:0p/lyso species) increased by 2-fold, and (4) GPE increased by 4-fold (Fig. 23), it is
fair to suggest that LPE-rich SFA were preferentially further degraded into GPE. An
increase in GPE level suggests that the balance between LPE hydrolysis and re-acylation
processes were affected in favor of hydrolysis. Moreover, an increase in the cellular level
of lyso-PE-Pls suggests an increase in PLA2 activity and a decrease in the activity of
lysoplasmalogenase that attaches an acyl chain on this species to re-form PE-Pls (Fig.
23). Interestingly, cells pre-treated with ME displayed a completely opposite response to
H2O2 for their contents in PUFA-rich LPE, lyso-PE-Pls, and GPE (Fig. 23). In fact, these
cells displayed a decrease in PUFA-rich LPE (20%), lyso-PE-Pls (17%), and GPE (64%)
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relative to corresponding controls (ME treated cells; Fig. 23). The pool of SFA-rich LPE
decreased by 8%. Thus, the ME + H2O2 group shows low levels of PE-Pls degradation
by-products and relatively high cellular levels of PE-Pls as described above. The
probable explanations could be that ME + H2O2 treatment (1) increased the activity of
lyso-acyltransferase enzymes that re-acylate LPE species to generate PE, (2) decreased
the activity of PLA2 or increased the activity of lysoplasmalogenase that attaches an acyl
chains to lyso-PE-Pls species to form PE-Pls, and/or (3) decreased the activity of
hydrolases that catalyze the hydrolysis of LPE to form GPE and fatty aldehydes (Fig. 23).
It has been reported that high levels of lysoplasmalogens are capable of lysing the cell
membranes because of their amphiphilic nature (237, 238). In order to prevent toxicity,
lysoplasmalogens are maintained at very low levels by lysoplasmalogenase (234, 236)
(239). Other adversary effects of elevated lysoplasmalogens include modulating the
activities of various enzymes (240), increasing the membrane fluidity (255), inhibiting
the cholinergic signal transduction (242) and activating the cAMP dependent protein
kinase A (243).

6.1.3 Hypothetical mechanisms of myo-inositol plus ethanolamine-mediated N2A cell
protection against H2O2-induced oxidative stress
H2O2 treatment decreased the cellular levels of PE-Pls and increased their
degradation by-products (LPE and GPE). Nine out of twelve LPE species measured
lacked acyl chains at sn-1 position of their glycerol backbones, suggesting an increase in
vinyl ether bond oxidation, PLA1 activity or both. Since the PE pool was not affected by
H2O2 treatment, we suggest that majority of LPE and GPE generated were from the
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degradation of PE-Pls species. It has been reported that vinyl ether bond is more
susceptible to oxidation than the corresponding ester bond linking the phospholipid

Figure 23. A diagram summarizing the effects of H2O2 treatment on PE-Pls species and the
hypothetical mechanisms for ME-mediated protection against H2O2-induced PE-Pls
degradation. See abbreviations on pages Xii and Xiii.

moieties to their glycerol backbone (3, 5, 39-41). This bond may preferentially undergo
ROS-mediated hydrolysis as compared to free radical attack of olefinic residues in the sn2 position of diacyl-phospholipids that are embedded in the hydrophobic domain of cell
membranes (19, 147, 148). Neural cells are particularly vulnerable to oxidative injury
because they contain high levels of PUFAs (51) and don’t possess sufficient reduced
glutathione (139). It is possible that all these factors contributed to PE-Pls loss in H2O2
treated cells. Elevated levels of ROS inflict damage to neural membranes, changing not
only their fluidity (140), but also decreasing activities of other membrane actors such as
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membrane-bound enzymes, ion channels, and receptors (141). It has also been reported
that they are capable of inducing alterations in cell signaling (142, 143) and surface
charge (51). Although ME pre-treatment protected N2A cells against H2O2-induced
toxicity, it not known by which mechanisms this happened. However, we cannot rule out
the possibility that by increasing the cellular levels of PE-Pls, these species served as a
sacrificial trap for ROS when cells were exposed to H2O2. It is also possible that ME
enhanced the cell viability to H2O2-induced toxicity by maintaining Etn phospholipid
homeostasis. This is supported by the observations that cell viability strongly correlated
with the baseline level of PE-Pls (r2 = 0.95) prior to H2O2 exposure. Pre-treating cells
with ME provided substrates for the synthesis of new PE-Pls to replenish those lost due
to H2O2-induced degradation. This assertion is support by our data showing that ME
increased the pool of PE-Pls precursors (AAPE) by 73% prior to H2O2 exposure.
Maintaining a normal level of PE-Pls and LPE after exposure to H2O2 supports our
assertion that pre-treating cells with ME preserved homeostasis through balancing PE-Pls
degradation, de novo synthesis and remodeling. This is supported by our data which show
that the level of myo-inositol in ME + H2O2 group dropped to the level below that of the
corresponding control (ME), suggesting that it was actively being utilized, presumably
for the synthesis of PE-Pls.
Establishing homeostasis of phospholipids requires a balance between
biosynthesis, degradation and remodeling (52). If degrading PE-Pls was the mechanism
of ME-induced protection against oxidative stress, we would have observed a significant
increase in LPE and/or GPE. However, this wasn’t the case. Assuming that PE-Pls were
also degraded under ME + H2O2 treatment, a couple of possibilities could explain these
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observations. (1) Increasing PE-Pls containing SFA+MUFA may have strengthened the
membrane integrity, decreasing its susceptibility to oxidative damage. Peroxidized
phospholipids in neural membranes can result in a membrane-packing defect, thus,
facilitating PLA2 access to the sn-2 ester bond for hydrolysis (51). Our data indicate that
lyso-PE-Pls strongly correlated (r2 > 0.5) with nine out of twelve probable PE-Pls parents
in H2O2 group, whereas in ME + H2O2 group this species only correlated with five PE-Pls
species. These data suggest that plasmalogen-selective PLA2 was relatively more active
in H2O2 group than in ME + H2O2 group. Plasmalogens are known to have a tendency of
packing more closely with one another, thus reducing the membrane fluidity and passive
ion permeability (43). Additionally, SFA pack more tightly than PUFA. Maybe both
factors combined serve to decrease membrane fluidity, which may affect access of ROS
to membrane lipids. (2) An increase in SFA + MUFA-rich PE-Pls may have also served
as a reservoir that can be sacrificed in response to H2O2 and that is protective.
6.2 CONCLUSIONS
Our data demonstrate that the levels of PE-Pls in neural cells can be enhanced by
ME treatment. They also indicate that increasing the baseline levels of PE-Pls in these
cells can provide protection against oxidative stress. Although the mechanisms behind the
ME-mediated cell protection against oxidative stress are not known, these show that there
may be a link between PE-Pls levels and cells protection, more specifically the oxidation
of vinyl ether linkage. Understanding this mechanism has an enormous significance for
the researchers and pharmaceutical industries as well. The ME-mediated increase in
cellular levels of PE-Pls may serve as a potential approach to enhance the brain’s ability
to reduce neurological sequelae of hazardous chemical exposure due to oxidative stress.
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More research could be tailored to designing new preventive and therapeutic strategies
that increase the PE-Pls levels in the cells to combat pathophysiologies associated with
cellular PE-Pls deficiency, and deleterious effects that may results from oxidative damage
or toxicity. A neuroprotective approach could be developed to address a wide spectrum of
stressors on brain and cognitive function, enhancing brain resiliency.
6.3 FUTURE DIRECTIONS
It has been demonstrated that the rate-limiting step in the biosynthesis of
plasmalogens is catalyzed by a peroxisomal fatty acyl-CoA reductase 1 (FAR 1) enzyme
(63). This enzyme supplies the fatty alcohols required for the formation of ether-linked
bonds that will become vinyl ether-linked bonds in plasmalogens (Fig. 4). Reports show
that the activity of FAR1 is increased in plasmalogen-deficient cells which can be
normalized by supplying the cells with plasmalogens (63, 259). The cellular activity of
this enzyme is controlled in the response to the levels of plasmalogens (through a
negative feedback mechanism) by increasing the rate of its degradation (63). One of the
future directions include inhibiting the FAR1 and test if (a) the increase in PE-Pls and PE
seen with ME treatment is reduced; (2) the protection against oxidative stress is
eliminated. This will be achieved by establishing two N2A cell colonies: a colony of cells
that lack FAR 1 enzyme (knocked out) and a normal colony (control). It is expected that
the effects of ME on Etn PLs in FAR 1-deficient cells will be reduced in comparison to
the control cells. Similarly, it is also expected that the protection to H2O2 exposure seen
with ME pre-treatment will also be eliminated.
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Other important issues that need to be addressed include testing the activities
plasmalogen-selective-PLA2, PLA1, lyso acyltransferase and lysoplasmalogenase
enzymes under ME and H2O2 treatments. Our data show that H2O2 increased the levels of
lyoplasmalogen (18:0p/lyso species) by 2-fold relative to the control. This species is
generated by plasmalogen-selective-PLA2 when it cleaves the acyl chain at the sn-2
position of plasmalogen. Interestingly, this effect was inhibited in ME + H 2O2 treatment.
It has been shown that H2O2 induces the translocation of cytosolic PLA2 (cPLA2) to the
cell membrane of fibroblasts and increases the activity due to substrate availability by the
action of ROS on membranes (153, 260). However, it is not known if plasmalogenselective PLA2 responds in the same way to H2O2. Our data suggest that H2O2 increased
the activity of plasmalogen-selective-PLA2 and the effect was inhibited under ME + H2O2
treatment. It is worthy to run enzyme activity assays and check the status of this enzyme
under these treatments. Similarly, the status of PLA1 needs to be assessed. An increase in
PLA1 activity may probably be linked to a decrease in PE-Pls levels observed under
H2O2.
Lyso acyltransferases, hydrolases and lysoplasmalogenases are among the
enzymes that control the levels of LPE in the cells. Our data show an overall 39%
increase in LPE and a 4-fold increase in GPE levels following H2O2 exposure. However
ME + H2O2 displays opposite effects on these metabolites (an overall 13% and 64%
decrease in LPE and GPE, respectively). These differences could reflect how each
treatment affected the enzyme activities. Our data suggest that H2O2 enhanced the
enzyme activities while the ME + H2O2 blocked this effect. It will be interesting to carry
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out the activity assays for lyso acyltransferases, hydrolases and lysoplasmalogenases
under these treatments.
In our study, we assessed how each treatment affected the levels of Etn PLs in
N2A cells. However, we only measured LPE and GPE as the degradation by-products of
PE-Pls and PE. We did not assess the levels of other products. Studies have shown that
oxidation by-products of PE-Pls’s vinyl ether bond include LPE (19, 178, 261-264)
formyl-GPE (19, 264) fatty aldehydes and hydroxy aldehydes (19). However, the study
done by Wynalda and Murphy (19) reported that the formation of formyl products from
PE-Pls’s oxidation is negligible. Stadelman-Ingrand et al. (18) observed that fatty
aldehydes and hydroxy aldehydes generated from sn-1 position of plasmalogens
following a UV irradiation are further oxidized as soon as they are produced. Although
these observations suggest that a quantification of formyl-GPE, fatty and hydroxy
aldehydes cannot give an accurate account on PE and PE-Pls’s degradation patterns, at
least this information combined with the LPE measurements can enhance the evaluation
on how the treatments affected these Etn PL in N2A cells. Therefore, it will be worthy to
also examine the levels of formyl-GPE, fatty aldehydes and hydroxy aldehydes in the
cells following H2O2 and ME + H2O2 treatments.
Lastly, other set of experiments that are worthy to carry out include checking the
levels of ROS in the cells following H2O2 and ME + H2O2 treatments. Procedures for
assessing the generation of superoxide radicals and H2O2 in the cells have been published
(265). These experiments will provide additional information on the level of oxidants in
the cells which can be linked to the levels of LPE.
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